{"text": "Factor Xa inhibitors can block the formation of thrombin rather than the inhibition of thrombin activity [ 16 ] .Currently , there are three injectable indirect factor Xa inhibitors in various stages of development : fondaparinux , idraparinux , and idrabiotaparinux ( Table 2 ) .", "label": "", "metadata": {}, "score": "24.884861"}
{"text": "Factor - specific anticoagulants have been proven safe and effective , and recently factor Xa inhibitors have emerged as a treatment alternative to heparins and VKA .", "label": "", "metadata": {}, "score": "28.134296"}
{"text": "Therefore , this class of drug will continue to have a major impact in the future management of thrombosis .The newly developed oral antithrombin and anti - Xa agents are mono - therapeutic and will require clinical validation in specific indications .", "label": "", "metadata": {}, "score": "28.560783"}
{"text": "Evidence of the newer , longer acting factor Xa inhibitors such as idraparinux and idrabiotaparinux is clearly lacking at present .Conflict of Interests .The authors do not report any conflict of interests regarding this work .", "label": "", "metadata": {}, "score": "28.835121"}
{"text": "To overcome these limitations , new oral anticoagulants such as factor Xa inhibitors and direct thrombin inhibitors have been developed .The aim of this article is to systematically review the phase 3 clinical trials of new oral anticoagulants in common medical conditions .", "label": "", "metadata": {}, "score": "30.672758"}
{"text": "Two second - generation direct oral Factor Xa inhibitors -- rivaroxaban , which has been approved in the EU and Canada , and apixaban -- are currently in the final stages of clinical development .", "label": "", "metadata": {}, "score": "31.192692"}
{"text": "In this paper , we examine the role of injectable factor Xa inhibitors in cancer patients , focusing on fondaparinux , the only such agent yet approved by the US Food and Drug Administration ( FDA ) .", "label": "", "metadata": {}, "score": "31.956913"}
{"text": "In addition , they have potential for multiple drug - drug interactions , which are often clinically important because of their narrow therapeutic index .In the past decade two classes of novel oral anticoagulants have been developed : direct thrombin inhibitors and factor Xa inhibitors .", "label": "", "metadata": {}, "score": "32.562763"}
{"text": "All these drugs are direct anticoagulant , orally effective , without the need for adaptation to hemostasis test .All the anti - Xa factor drugs are metabolized by liver cytochromes and then contra - indicated in case of liver insufficiency .", "label": "", "metadata": {}, "score": "32.953682"}
{"text": "Shorter acting anticoagulants such as heparins should be used in surgical settings where epidurals are indicated .Idrabiotaparinux .Idrabiotaparinux is another long - acting factor Xa inhibitor ( 3.0 mg SQ weekly dose ) that has a . of up to 60 days and has no antidote ( Table 2 ) .", "label": "", "metadata": {}, "score": "34.86066"}
{"text": "Fondaparinux is a new synthetic factor Xa inhibitor ( molecular weight : 1.726 Dalton ) with superior efficacy-/safety - profile compared to low molecular weight heparins ( LMWH ) and exerts in vitro no cross - reactivity with HIT - antibodies .", "label": "", "metadata": {}, "score": "34.91423"}
{"text": "We also stratified pooling and meta - analysis of event data by pharmacological class ( direct thrombin inhibitors or factor Xa inhibitor ) .The factor Xa inhibitors also decreased major bleeding , driven by the rivaroxaban studies , as discussed above .", "label": "", "metadata": {}, "score": "36.413506"}
{"text": "These patients were randomly assigned in a 1:1 ratio to receive apixaban 5 mg twice daily or matching placebo .Rivaroxaban .Rivaroxaban is another oral , direct acting , reversible factor Xa inhibitor with a rapid onset of action and dose - proportional pharmacokinetics and pharmacodynamics [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "36.69194"}
{"text": "Abbreviations : vitamin k antagonist ( VKA ) ; low - molecular - weight heparin ( LMWH ) ; unfractioned heparin ( UFH ) .In recent years , more targeted anticoagulants such as fondaparinux ( 1728 Da or pentasaccharides ) have emerged that specifically target factor Xa .", "label": "", "metadata": {}, "score": "36.752728"}
{"text": "In particular clinical circumstances where a measure of anticoagulant efficacy is deemed necessary , specific assay of anti - Xa activity is appropriate , the result being expressed as concentration of the anticoagulant used .", "label": "", "metadata": {}, "score": "36.88349"}
{"text": "We also addressed the safety of using factor Xa inhibitors for the prevention and long - term treatment of VTE in special populations of cancer patients , such as patients who are obese , have renal insufficiency , or have a high risk of bleeding .", "label": "", "metadata": {}, "score": "37.070892"}
{"text": "Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa , which is located at the crossing of both the intrinsic and extrinsic pathways .", "label": "", "metadata": {}, "score": "38.39098"}
{"text": "Lassen MR , Bauer KA , Eriksson BI , Turpie AG .Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip - replacement surgery : a randomised double - blind comparison .", "label": "", "metadata": {}, "score": "38.752525"}
{"text": "Aim of the study : Although Fondaparinux is not approved for the management of acute HIT syndrome , we report cases where Fondaparinux is used in - label for prevention of venous thromboembolism in high risk patients with history of HIT .", "label": "", "metadata": {}, "score": "38.992836"}
{"text": "Evidence suggests that fondaparinux should be used in the acute phase of VTE treatment , but evidence of the efficacy and safety for long - term treatment is lacking , especially in cancer patients .", "label": "", "metadata": {}, "score": "39.015354"}
{"text": "Four anticoagulant agents are currently commercially available for ACS , namely unfractionated heparin ( UFH ) , enoxaparin , bivalirudin and fondaparinux .We describe the advantages of fondaparinux and the reasons that have hampered its uptake into routine management of ACS .", "label": "", "metadata": {}, "score": "39.111534"}
{"text": "Conclusion .More targeted anticoagulants such as factor Xa inhibitors are being investigated .To date , fondaparinux has received FDA approval for the prevention and treatment of VTE .", "label": "", "metadata": {}, "score": "39.331665"}
{"text": "Fondaparinux .Pharmacodynamic Profile of Indirect Factor XaInhibitor .After activation of the coagulation cascade by either the intrinsic or extrinsic pathways , the generation of factor Xa is amplified .", "label": "", "metadata": {}, "score": "39.928036"}
{"text": "Objective To critically review the effectiveness of the novel oral anticoagulants ( rivaroxaban , dabigatran , ximelagatran , and apixaban ) in the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "40.231377"}
{"text": "Eriksson BI , Bauer KA , Lassen MR , Turpie AG .Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip - fracture surgery .", "label": "", "metadata": {}, "score": "40.747955"}
{"text": "There are case reports and limited laboratory studies alluding to judicious use of recombinant factor VIIa ( rVIIa ) for reversal of bleeding associated with fondaparinux .", "label": "", "metadata": {}, "score": "40.790867"}
{"text": "Site of Action for New Anti - thrombotic Agents : .Site of Action for New Anti - thrombotic Agents Fibrin Clot Intrinsic Extrinsic XII VII VIII IX XI Fibrinogen II V T issue F actor X Direct Xa Inhibitors \" - xaban \" AT Indirect Xa Inhibitors \" - parinux \" Direct Thrombin Inhibitors \" - gatran \" warfarin .", "label": "", "metadata": {}, "score": "41.05264"}
{"text": "Fondaparinux - specific anti - Xa assay should be used to monitor the anti - Xa levels of fondaparinux in patients who have unstable renal function , are elderly , are morbidly obese , or have a low BMI [ 35 ] .", "label": "", "metadata": {}, "score": "41.174538"}
{"text": "The selective thrombin inhibitor bivalirudin with a provisional glycoprotein IIb / IIIa inhibitor ( GPI ) has been shown to be comparable to heparin plus GPI in the rates of ischemic events but to significantly reduce the risk of bleeding complications in patients with acute coronary syndromes .", "label": "", "metadata": {}, "score": "41.21922"}
{"text": "Gerotziafas and his colleagues have concluded that recombinant factor VII ( rFVIIa ) partially reverses the effect of fondaparinux on inhibition of thrombin generation .In their study , the effect of concentrations of fondaparinux from 0.1 to 1.0 \u03bc g / mL ( concentrations required for prophylaxis and treatment of VTE ) and the influence of rVIIa at 1 \u03bc g / mL on various parameters such as lag time ( minutes ) , thrombin .", "label": "", "metadata": {}, "score": "41.237"}
{"text": "Comparisons with other studies .The novel oral anticoagulants have been tested in clinical trials for other indications , including thromboprophylaxis in atrial fibrillation , medical and surgical inpatients , and acute coronary syndromes .", "label": "", "metadata": {}, "score": "41.501896"}
{"text": "Therefore , drugs that inhibit P - glycoprotein , such as quinidine , verapamil and amiodarone , will increase the plasma levels of dabigatran [ 43 ] .", "label": "", "metadata": {}, "score": "41.50657"}
{"text": "Slide 11 : .Fondaparinux and idraparinux are two new parenteral indirect factor Xa inhibitors .Fondaparinux : A synthetic analog of the antithrombin -binding pentasaccharide sequence found in heparin and low - molecular - weight heparin , fondaparinux binds antithrombin and enhances its reactivity with factor Xa .", "label": "", "metadata": {}, "score": "41.87178"}
{"text": "In addition , the comparator arm might have been placebo , parenteral anticoagulants , or vitamin K antagonists , depending on the study .For example , patients with acute coronary syndromes were at a higher risk of bleeding ( 2.2 % for rivaroxaban in the ATLAS ACS 2-TIMI 51 trial ) as they were typically treated with antiplatelet agents .", "label": "", "metadata": {}, "score": "42.044975"}
{"text": "Our analyses of an individual patient database involving ? 13 000 surgical and medical patients receiving fondaparinux or control for the prevention of venous thromboembolism showed that patients who develop major bleeding have an almost 7-fold increased risk of death .", "label": "", "metadata": {}, "score": "42.1756"}
{"text": "Dialysis patients with an acute medical illness who are hospitalized should receive prophylaxis with UFH [ 34 ] .Monitoring Anti - Xa Levels in Patients Receiving Fondaparinux .", "label": "", "metadata": {}, "score": "42.26055"}
{"text": "Agnelli G , Gallus A , Goldhaber SZ , Hass S , Huisman MV , Hull RD , et al .Treatment of proximal deep - vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban ( bay 59 - 7939 ) : the ODIXa - DVT ( Oral Direct Factor Xa inhibitor BAY 59 - 7939 in patients with acute symptomatic deep - vein thrombosis ) study .", "label": "", "metadata": {}, "score": "42.308556"}
{"text": "Though the direct thrombin inhibitor ximelagatran was withdrawn from the market in 2006 because of concerns over hepatotoxicity , we elected to include these data for completeness .", "label": "", "metadata": {}, "score": "42.393845"}
{"text": "Modulation of endogenous fibrinolytic activity These include inhibitors of PAI-1 , activated TAFI ( TAFIa ) , or factor XIIIa .PAI-1 inhibitors : inhibition of PAI-1 results in increased endogenous fibrinolytic activity .", "label": "", "metadata": {}, "score": "42.416588"}
{"text": "Turpie AG , Bauer KA , Eriksson BI , Lassen MR .Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip - replacement surgery : a randomised double - blind trial .", "label": "", "metadata": {}, "score": "42.530304"}
{"text": "Idraparinux , another long - acting factor Xa inhibitor ( 2.5 mg SQ weekly dose ) , currently is being investigated in clinical trial for the prevention and treatment of VTE .", "label": "", "metadata": {}, "score": "42.565742"}
{"text": "fondaparinux ? venous thromboembolism V potentially preventable cause of death in hospitalized patients.2,3 Anticoagulants are effective for the prevention of VTE but are associated with an increased risk of bleeding .", "label": "", "metadata": {}, "score": "42.74491"}
{"text": "Several other oral anticoagulants such as edoxaban , betrixiban are also in clinical development .A parenteral anti Xa agent with strong anticoagulant activity namely Otamixaban ( sonofi - aventis , Paris , France ) is also in advanced clinical stages as a parenteral anticoagulant in percutaneous intervention .", "label": "", "metadata": {}, "score": "42.75935"}
{"text": "Approved by both Europe and Canada : shortterm thromboprophylaxis in pts undergoing orthopedic procedures .Ximelagatran : .Ximelagatran First oral direct thrombin inhibitor Prodrug of melagatran .", "label": "", "metadata": {}, "score": "42.770393"}
{"text": "With these new anticoagulants , management of hemorrhagic events can be more difficult due to the lack of a specific antidote .Pro - hemostatic substances have exhibited efficacy in animal models but results are still insufficiently documented in clinical practice .", "label": "", "metadata": {}, "score": "42.93787"}
{"text": "Agnelli G , Bergqvist D , Cohen AT , Gallus AS , Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high - risk abdominal surgery .", "label": "", "metadata": {}, "score": "43.08893"}
{"text": "In line with the results from these studies , however , it seems that novel oral anticoagulants might be an effective and safe alternative to conventional treatment for acute venous thromboembolism .", "label": "", "metadata": {}, "score": "43.344475"}
{"text": "This paper will examine the role of these agents , focusing on fondaparinux , for the prevention and treatment of VTE in cancer patients .Introduction .", "label": "", "metadata": {}, "score": "43.73723"}
{"text": "However , this genetic association and the role of COX-2 in CVD remain controversial ... .Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non - ST - segment elevation acute coronary syndromes : an individual patient - level combined analysis of the Fifth and Sixth Organization to Ass .", "label": "", "metadata": {}, "score": "43.88215"}
{"text": "Tissue Factor Pathway Inhibitor : .Inhibitors of propagation of coagulation : .Inhibitors of propagation of coagulation Drugs that block factor IXa , factor Xa or their respective cofactors , factor VIIIa and factor Va , inhibit the propagation of coagulation .", "label": "", "metadata": {}, "score": "44.020336"}
{"text": "All of the novel oral anticoagulants ( except in the small apixaban study ) showed a trend towards lower rates of major bleeding compared with vitamin K antagonists , but this was significant only for rivaroxaban .", "label": "", "metadata": {}, "score": "44.043274"}
{"text": "10.1056/NEJMoa011099 View Article PubMed .Eriksson BI , Bauer KA , Lassen MR , Turpie AG , Steering Committee of the Pentasaccharide in Hip - Fracture Surgery Study : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip - fracture surgery .", "label": "", "metadata": {}, "score": "44.118675"}
{"text": "The authors concluded that administration of rFVIIa as a single 90 \u03bc /kg IV bolus could neutralize the anticoagulant effect of fondaparinux ( 10 mg ) [ 64 ] .", "label": "", "metadata": {}, "score": "44.138214"}
{"text": "Three years earlier , the patient had a history of HIT with thrombosis due to nadroparin .The authors concluded that fondaparinux should be used with caution in patients with HIT [ 55 ] .", "label": "", "metadata": {}, "score": "44.295498"}
{"text": "Anticoagulants in development .( Ultra-)LMWHs are currently being developed for different indications , amongst others bemiparin ( Rovi , Madrid , Spain ) and semuloparin ( sonofi - aventis , Paris , France ) .", "label": "", "metadata": {}, "score": "44.556503"}
{"text": "This translates clinically into a more predictable dose - response effect and a lower potential for LMWHs to induce effects such as heparin - induced thrombocytopenia .", "label": "", "metadata": {}, "score": "44.73512"}
{"text": "The results of this study showed that the safety and efficacy of fondaparinux for initial treatment of VTE was comparable to heparin across different body weight and BMI categories [ 28 ] .", "label": "", "metadata": {}, "score": "44.811707"}
{"text": "This study examined the efficacy and safety of the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes undergoing cardiac catheterization .BACKGROUND : Argatroban is a direct - thrombin inhibitor approved for use in percutaneous coronary intervention in patients with heparin - induced thrombocytopenia .", "label": "", "metadata": {}, "score": "44.827457"}
{"text": "10.1080/110241598750005534 View Article PubMed .Eriksson BI , Lassen MR , PENTasaccharide in HIp - FRActure Surgery Plus Investigators : Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery : a multicenter , randomized , placebo - controlled , double - blind study .", "label": "", "metadata": {}, "score": "44.84962"}
{"text": "[ 40 ] .Methodology of determining factor Xa activity of fondaparinux requires a chromogenic assay that is calibrated to fondaparinux but not to LMWH or UFH .", "label": "", "metadata": {}, "score": "44.87601"}
{"text": "Study selection Randomised controlled trials of novel oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism .Selected outcomes were recurrent events , major bleeding , and all cause mortality .", "label": "", "metadata": {}, "score": "44.989372"}
{"text": "11 , pp .1605 - 1611 , 2006 .View at Google Scholar \u00b7 View at Scopus . F. Depasse , G. T. Gerotziafaz , J. Busson , P. van Dreden , and M. M. Samama , \" Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux ( Arixtra ) anti - Xa activity , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "45.0733"}
{"text": "J Bone Joint Surg Am 2001 , 83-A : 900 - 906 .PubMed .Bauer KA , Eriksson BI , Lassen MR , Turpie AG , Steering Committee of the Pentasaccharide in Major Knee Surgery Study : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective hip - replacement surgery .", "label": "", "metadata": {}, "score": "45.32193"}
{"text": "Over the last 10 years , UFH has been replaced as the reference standard anticoagulant in VTE management by the LMWHs .Three LMWHs are currently available in the USA : enoxaparin , dalteparin , and tinzaparin .", "label": "", "metadata": {}, "score": "45.49946"}
{"text": "Evaluation of : Berger JS , Krantz MJ , Kittelson JM , Hiatt WR .Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease : a meta - analysis of randomized trials .", "label": "", "metadata": {}, "score": "45.574707"}
{"text": "J Thromb Haemost 2008 , 6(8):1313 - 1318 .View Article PubMed .Lassen MR , Davidson BL , Gallus A , Pineo G , Ansell J , Deitchman D : The efficacy and safety of apixaban , an oral , direct factor Xa inhibitor , as thromboprophylaxis in patients following total knee replacement .", "label": "", "metadata": {}, "score": "45.65163"}
{"text": "This variation among the LMWHs gives rise to the different pharmacokinetic and pharmacodynamic profiles of the different LMWH agents [ 14 ] .Fondaparinux is a synthetic pentasaccharide with a molecular weight of 1,728 Da containing an AT - binding domain modified from that found in UFH and LMWHs to increase its affinity for AT .", "label": "", "metadata": {}, "score": "45.66461"}
{"text": "To prevent users from facing this , Use HTTPS option .Abstract .Background .Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease .", "label": "", "metadata": {}, "score": "45.964737"}
{"text": "Comparative Efficacy in VTE Prevention Trials . )The patients who received fondaparinux had a 0.4 % incidence of major bleeding , and their 32-day mortality rate was 3.3 % , while patients who received the placebo had a 32-day mortality rate of 6.0 % ( . )", "label": "", "metadata": {}, "score": "46.000378"}
{"text": "Currently available oral antiplatelet agents are aspirin and the thienopyridine P2Y(12)-receptor antagonists .These agents are used frequently in combination among patients with coronary artery disease , and also following percutaneous coronary intervention to reduce major adverse cardiovascular events .", "label": "", "metadata": {}, "score": "46.0511"}
{"text": "Our analyses confirm that major bleeding in hospitalized patients is a powerful predictor of death .The trend of reduced mortality with fondaparinux despite the increase in major bleeding underscores the importance of using proven effective thrombopro- phylaxis strategies according to the overall results of randomized controlled trials , even if drugs increase the risk of bleeding .", "label": "", "metadata": {}, "score": "46.106815"}
{"text": "The use of rVIIa in bleeding episodes associated with fondaparinux should be done with caution given the cost , risk of thrombotic events , and partial reversibility .", "label": "", "metadata": {}, "score": "46.29465"}
{"text": "Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported ... .", "label": "", "metadata": {}, "score": "46.419556"}
{"text": "PubMed .Walenga JM , Jeske WP , Samama MM , Frapaise FX , Bick RL , Fareed J : Fondaparinux : a synthetic heparin pentasaccharide as a new antithrombotic agent .", "label": "", "metadata": {}, "score": "46.529488"}
{"text": "Fondaparinux can be differentiated further from the polypharmacologic effects of UFH and LMWHs , as it does not release tissue factor pathway inhibitor [ 16 ] .", "label": "", "metadata": {}, "score": "46.638405"}
{"text": "Close attention to estimation of the glomerular filtration rate ( GFR ) is imperative in dosing of antithrombotics such as fondaparinux that has a long .", "label": "", "metadata": {}, "score": "46.883778"}
{"text": "An ideal antithrombotic agent should reduce ischemic complications while keeping bleeding events to a minimum .Heparins , both unfractionated and low molecular weight , reduce ischemic outcomes but also significantly increase the risk of major and minor bleeding .", "label": "", "metadata": {}, "score": "46.89319"}
{"text": "The clinical outcomes associated with GIB in this setting have not been systematically studied .BACKGROUND : Clopidogrel has been utilized as an antiplatelet therapy for patients undergoing stent implantation .", "label": "", "metadata": {}, "score": "46.924232"}
{"text": "4 , pp .198 - 203 , 2008 .View at Google Scholar \u00b7 View at Scopus .R. M. Kalicki , F. Aregger , L. Alberio , B. L\u00e4mmle , F. J. Frey , and D. E. Uehlinger , \" Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "46.987083"}
{"text": "Rivaroxaban is a competitive reversible antagonist of activated factor X ( Xa ) .Rivaroxaban 10 mg tablets are well absorbed ( 80 % bioavailability ) with no effect of food on absorption or pharmacokinetic parameters .", "label": "", "metadata": {}, "score": "47.006554"}
{"text": "We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI ... .Point - of - care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease .", "label": "", "metadata": {}, "score": "47.094273"}
{"text": "Because it binds to factor X with high affinity , NAPc2 has a half - life of approximately 50 h after subcutaneous injection .Synthetic inhibitors .", "label": "", "metadata": {}, "score": "47.247482"}
{"text": "Lechler E , Schramm W , Flosbach CW : The venous thrombotic risk in non - surgical patients : epidemiological data and efficacy / safety profile of a low - molecular - weight heparin ( enoxaparin ) .", "label": "", "metadata": {}, "score": "47.264107"}
{"text": "In this case , platelet activation was also observed with pharmacological doses of enoxaparin ( 0.1 U / mL ) , but not in the presence of fondaparinux [ 56 ] .", "label": "", "metadata": {}, "score": "47.371857"}
{"text": "Low - molecular - weight heparins ( LMWHs ) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic agents for the treatment of patients with acute coronary syndromes ( ACS ) .", "label": "", "metadata": {}, "score": "47.4678"}
{"text": "Interactions have been found with P - glycoprotein inhibitors ( quinidine , amiodarone ) with increased total dabigatran exposure .P - glycoprotein inducers may reduce systemic exposure of dabigatran .", "label": "", "metadata": {}, "score": "47.50676"}
{"text": "2008;10(suppl C):C8-C13 .Bauer KA , Eriksson BI , Lassen MR , Turpie AG .Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery .", "label": "", "metadata": {}, "score": "47.552414"}
{"text": "F. F. van Doormaal , A. T. Cohen , B. L. Davidson et al . , \" Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients : a subgroup analysis of the Van Gogh DVT trial , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "47.758778"}
{"text": "Given the need for subcutaneous route of administration , long term use of LMWH poses a problem .The new oral anticoagulants specifically target either thrombin or factor Xa ( Figure 1 ) , whereas warfarin inhibits synthesis of all vitamin K - dependant clotting factors .", "label": "", "metadata": {}, "score": "47.82515"}
{"text": "Fondaparinux has been shown to affect the protein S assay in vitro , resulting in false elevation of protein S levels ; however , the significance of these findings is yet to be determined [ 37 ] .", "label": "", "metadata": {}, "score": "47.857666"}
{"text": "Factor XIIIa inhibitors : Tridegin , a peptide isolated from the giant Amazon leech , Haementeria ghilianti , is a specific inhibitor of factor XIIIa and enhances fibrinolysis in vitro when added before clotting of fibrinogen .", "label": "", "metadata": {}, "score": "47.871437"}
{"text": "Briefly , VKAs inhibit the formation of factors II , VII , IX , X and the natural anticoagulant proteins C and S [ 12 ] .", "label": "", "metadata": {}, "score": "47.920258"}
{"text": "What is already known on this topic .Traditional treatment of acute venous thromboembolism with vitamin K antagonists is effective but is complex to manage and is associated with an increased risk of bleeding .", "label": "", "metadata": {}, "score": "47.951385"}
{"text": "Data were stratified according to different novel oral anticoagulants .The adjusted indirect comparison between rivaroxaban and dabigatran did not show superiority of either drug over the others for major bleeding ( 0.75 , 0.41 to 1.34 ) or the other endpoints .", "label": "", "metadata": {}, "score": "47.99176"}
{"text": "The fondaparinux 1.5-mg dosing schedule may be a safe and effective alternative to 2.5-mg recommended dose for the prevention of VTE ; however , determining the most effective dosing schedule for fondaparinux requires further trials and investigation .", "label": "", "metadata": {}, "score": "48.03578"}
{"text": "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long - term anticoagulant therapy ( RE - LY ) trial .", "label": "", "metadata": {}, "score": "48.062164"}
{"text": "Thromb Haemost 2010 , 104(3):642 - 649 .10.1160/TH10 - 02 - 0142 View Article PubMed .Fuji T , Fujita S , Tachibana S , Kawai Y : A dose - ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty .", "label": "", "metadata": {}, "score": "48.09173"}
{"text": "Miller CS , Grandi SM , Shimony A , Filion KB , Eisenberg MJ .Meta - analysis of efficacy and safety of new oral anticoagulants ( dabigatran , rivaroxaban , apixaban ) versus warfarin in patients with atrial fibrillation .", "label": "", "metadata": {}, "score": "48.165257"}
{"text": "What this study adds .A meta - analysis of all available data showed that the novel oral anticoagulants are associated with a similar risk of recurrence of acute venous thromboembolism compared with standard treatment with vitamin K antagonists .", "label": "", "metadata": {}, "score": "48.16545"}
{"text": "114 - 121 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .K. I. Sombolos , T. K. Fragia , L. C. Gionanlis et al . , \" Use of fondaparinux as an anticoagulant during hemodialysis : a preliminary study , \" International Journal of Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "48.20246"}
{"text": "\" We excluded patients receiving intravenous thrombolytic from our study .[ Show abstract ] [ Hide abstract ] ABSTRACT : Unfractionated heparin ( UFH ) , low molecular weight heparin or fondaparinux are recommended for venous thromboembolism ( VTE ) prophylaxis in acutely ill medical patients .", "label": "", "metadata": {}, "score": "48.39805"}
{"text": "However , the effectiveness of these agents has yet to be tested in vivo .The removal of these lysine residues decreases plasminogen and plasmin binding to fibrin , thereby retarding the lytic process .", "label": "", "metadata": {}, "score": "48.453804"}
{"text": "In contrast to the LMWHs , fondaparinux does not exhibit polypharmacologic action although thrombosis is a polypathologic process .Generic versions of the branded LMWHs are now available for clinical use .", "label": "", "metadata": {}, "score": "48.514694"}
{"text": "Of the currently available antithrombotics , the LMWH enoxaparin offers the most extensive clinical experience and the widest range of clinical indications including surgical and medical thromboprophylaxis , and inpatient and outpatient treatment of VTE .", "label": "", "metadata": {}, "score": "48.646976"}
{"text": "In this study , the authors found a decrease in the clot lysis time on addition of fondaparinux ( control . ) , and this effect lasted for up to 8 hours .", "label": "", "metadata": {}, "score": "48.70834"}
{"text": "Translation of the differences in chemical profiles of the parenteral anticoagulants to their clinical profile is not straightforward .Parenteral anticoagulants have different FDA - approved indications for VTE , and there are differences in the supporting clinical evidence .", "label": "", "metadata": {}, "score": "48.722816"}
{"text": "The therapeutic strategy is identical between DVT and PE treatment with an acute phase with either parenteral anticoagulants , especially low molecular weight heparins or fondaparinux , or by an intensive dose of direct oral anticoagulant such as rivaroxaban or apixaban .", "label": "", "metadata": {}, "score": "48.755806"}
{"text": "10.2165/0003088 - 200948010 - 00001 View Article PubMed .Buller H , Deitchman D , Prins M , Segers A : Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis .", "label": "", "metadata": {}, "score": "48.797405"}
{"text": "Fiessinger JN , Huisman MV , Davidson BL , Bounameaux H , Francis CW , Eriksson H , et al .Ximelagatran vs low - molecular - weight heparin and warfarin for the treatment of deep vein thrombosis : a randomized trial .", "label": "", "metadata": {}, "score": "48.834724"}
{"text": "Oral vitamin K antagonists ( warfarin ) are used for long - term anticoagulation [ 6 , 7 ] .The first of the new oral anticoagulants was the oral direct thrombin inhibitor ximelagatran .", "label": "", "metadata": {}, "score": "49.098965"}
{"text": "Each low - molecular - weight heparin is a distinct pharmacological entity with different licensed indications and available clinical evidence .Enoxaparin is the only low - molecular - weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment .", "label": "", "metadata": {}, "score": "49.214424"}
{"text": "10.1016/S0140 - 6736(02)08652-X View Article PubMed .Turpie AG , Bauer KA , Eriksson BI , Lassen MR , PENTATHALON 2000 Study Steering Committee : Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip - replacement surgery : a randomised double - blind trial .", "label": "", "metadata": {}, "score": "49.270878"}
{"text": "However , for patients who present with pulmonary embolism , the role of low - molecular - weight heparin is uncertain and unfractionated heparin remains widely used ... .", "label": "", "metadata": {}, "score": "49.284775"}
{"text": "The authors concluded that the role of fondaparinux in cases of suspected HIT might be as bridging until HIT is confirmed [ 51 ] .Several case reports in the literature have advocated the use of a therapeutic dose of fondaparinux in the management of HIT [ 52 ] .", "label": "", "metadata": {}, "score": "49.28942"}
{"text": "BACKGROUND : Bivalirudin is a direct thrombin inhibitor with several pharmacological advantages over heparin .It has been studied extensively in non - ST elevation acute 60 coronary syndromes ( NSTE - ACS ) and in percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "49.390087"}
{"text": "Fondaparinux binding to AT causes an approximate 300-fold increase in the rate at which AT inhibits factor Xa [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "49.442657"}
{"text": "Comparative Efficacy in VTE Treatment Trials .Primary data of fondaparinux for treatment of VTE cancer patients is also lacking .Two studies have shown the similar efficacy of fondaparinux versus LMWH and VKA for the initial phase of VTE treatment that enrolled 10 % of patients with cancer [ 24 , 25 ] .", "label": "", "metadata": {}, "score": "49.444366"}
{"text": "In contrast , in atrial fibrillation studies , the novel oral anticoagulants were associated with similar risk of major bleeding ( relative risk 0.88 , 95 % confidence interval 0.71 to 1.09 ) .", "label": "", "metadata": {}, "score": "49.53011"}
{"text": "Unfractionated and low - molecular - weight heparin as adjuncts to thrombolysis in aspirin - treated patients with ST - elevation acute myocardial infarction : a meta - analysis of the randomized trials .", "label": "", "metadata": {}, "score": "49.562492"}
{"text": "It has been hypothesized that the lower saccharide residue , the lower antigenicity [ 48 ] .Testing the sera of patients from 2 clinical trials , investigators showed that the PF4-fondaparinux complex , but not the PF4-LMWH complex , is readily recognized by antibodies generated during HIT and that the risk of HIT associated with fondaparinux is very low [ 49 ] .", "label": "", "metadata": {}, "score": "49.600136"}
{"text": "Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion : the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study .", "label": "", "metadata": {}, "score": "49.62358"}
{"text": "for prevention of venous thromboembolism as long as the risk of thromboembolism persists .Results : In six patients with a history of HIT Fondaparinux was successfully used for the prevention of venous thromboembolism in high risk patients : No HIT , venous thromboembolic events or bleedings were observed .", "label": "", "metadata": {}, "score": "49.760918"}
{"text": "Dosing of Fondaparinux in Underweight and Overweight Patients with Cancer .Pooled analysis of the effect of obesity ( cutoff , 30 kg / m 2 ) on outcomes in the Matisse trials ( Matisse - DVT and Matisse - PE ) has been reported .", "label": "", "metadata": {}, "score": "49.84463"}
{"text": "Eriksson BI , Lassen MR .Duration of prophylaxis against venous throm- boembolism with fondaparinux after hip fracture surgery : a multicenter , randomized , placebo - controlled , double - blind study .", "label": "", "metadata": {}, "score": "49.85661"}
{"text": "Third , the previously ob- served trend for a reduction in mortality with fondaparinux compared with control9was evident irrespective of whether patients experienced major bleeding .", "label": "", "metadata": {}, "score": "49.94538"}
{"text": "Eikelboom JW .Effect of fondaparinux 2.5 mg once daily on mortality : a meta - analysis of phase III randomized trials of venous thromboembolism prevention .", "label": "", "metadata": {}, "score": "50.091854"}
{"text": "Patients who developed major bleeding were older , were more likely to be male , had a lower body weight and lower creatinine clearance , and were more likely to be receiving fondaparinux .", "label": "", "metadata": {}, "score": "50.205956"}
{"text": "6 , pp .1200 - 1207 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. M. Samama and G. T. Gerotziafas , \" Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide ( fondaparinux ) , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "50.22632"}
{"text": "Secondly , most randomised controlled trials had an open label design because of the complexity and futility of monitoring international normalised ratio in the novel oral anticoagulant arm .", "label": "", "metadata": {}, "score": "50.238403"}
{"text": "Similarly , 3 - 5 weeks of extended - duration VTE prophylaxis with fondaparinux was shown to be effective and have a good safety profile after major lower limb surgery in patients with or without indwelling neuraxial or deep peripheral nerve catheters [ 51 ] .", "label": "", "metadata": {}, "score": "50.35252"}
{"text": "We also performed an adjusted indirect comparison analysis to evaluate potential risks / benefits of one novel oral anticoagulant over the other .The analysis of dabigatran and rivaroxaban did not show significant differences between the two drugs - the point estimate tended to favour rivaroxaban but the upper confidence limit crossed 1.0 in every case .", "label": "", "metadata": {}, "score": "50.520264"}
{"text": "Rivaroxaban is metabolised by liver enzymes , principally cytochrome P450 3A4 , and also by cytochrome -independent mechanisms .A number of small - molecule , orally administered direct Factor Xa inhibitors are currently in development .", "label": "", "metadata": {}, "score": "50.62403"}
{"text": "10.1056/NEJMoa011100 View Article PubMed .ENOXACAN Study Group : Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery : a double - blind randomized multicentre trial with venographic assessment .", "label": "", "metadata": {}, "score": "50.636658"}
{"text": "The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation ( ROCKET AF ) [ 23 , 24 ] was conducted in 14,264 patients of non - valvular atrial fibrillation .", "label": "", "metadata": {}, "score": "50.6599"}
{"text": "Patients randomised to ximelagatran received dummy low molecular weight heparin with dummy vitamin K antagonists during the initial phase of the study .Risk of bias assessment .", "label": "", "metadata": {}, "score": "50.68888"}
{"text": "Rivaroxaban and dabigatran are also superior to the conventional agents in the management of symptomatic venous thromboembolism .However , compared to enoxaparin , apixaban and rivaroxaban use lead to significantly increased bleeding risk in medically ill patients .", "label": "", "metadata": {}, "score": "50.793327"}
{"text": "Buller HR , Lensing AWA , Prins MH , Agnelli G , Cohen A , Gallus AS , et al .A dose - ranging study evaluating once - daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis : the Einstein - DVT Dose - Ranging Study .", "label": "", "metadata": {}, "score": "50.988674"}
{"text": "The use of fondaparinux in patients with HIT has been challenged .The authors indicated that in rare cases fondaparinux can activate antibodies against PF4 that resemble the antibodies in HIT [ 54 ] .", "label": "", "metadata": {}, "score": "51.0001"}
{"text": "To obtain estimates of the efficacy and safety of pre - operative aspirin in patients undergoing coronary artery bypass grafting ( CABG ) ... .Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke : a critical review .", "label": "", "metadata": {}, "score": "51.10166"}
{"text": "6 , pp . 340S-380S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .K. H. M. Kuo and M. J. Kovacs , \" Successful treatment of heparin induced thrombocytopenia ( HIT ) with fondaparinux , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.234276"}
{"text": "A 600-mg loading dose of clopidogrel compared with 300 mg provides more rapid ... .Achieving optimal outcomes in patients with acute coronary syndromes depends on early reperfusion supported by rapid initiation of adjunctive antiplatelet and anticoagulant therapy .", "label": "", "metadata": {}, "score": "51.26645"}
{"text": "The relation between change in HDL - C level and clinical endpoint may be drug dependent , which limits the use of HDL - C as a surrogate marker of coronary events .", "label": "", "metadata": {}, "score": "51.33939"}
{"text": "This subgroup analysis of cancer patients showed that during the entire study period there was a trend toward higher rates of recurrent VTE in fondaparinux - treated patients ( 12.7 % in the fondaparinux group versus 5.4 % in the enoxaparin group ; . )", "label": "", "metadata": {}, "score": "51.34288"}
{"text": "The effect of pre - operative aspirin on bleeding , transfusion , myocardial infarction , and mortality in coronary artery bypass surgery : a systematic review of randomized and observational studies .", "label": "", "metadata": {}, "score": "51.345406"}
{"text": "Buller H , Deitchman D , Prins M , Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis .", "label": "", "metadata": {}, "score": "51.385536"}
{"text": "10.1001/archinte.158.14.1525 View Article PubMed .Planes A , Vochelle N , Darmon JY , Fagola M , Bellaud M , Huet Y : Risk of deep - venous thrombosis after hospital discharge in patients undergoing total hip replacement : double - blind randomised comparison of enoxaparin versus placebo .", "label": "", "metadata": {}, "score": "51.44392"}
{"text": "Meta - regression analysis on raising HDL - C drugs ( statins , fibrates , niacin ) in randomised controlled trials .The meta - regression analysis showed no significant association between change in HDL - C ( treatment vs comparator ) and log risk ratio ( RR ) of clinical endpoint ( non - fatal myocardial infarction or cardiac death ) .", "label": "", "metadata": {}, "score": "51.480843"}
{"text": "Current ACCP guidelines recommend LMWH , UFH , or fondaparinux for the short - term treatment of objectively confirmed VTE [ 7 ] .Treatment with a LMWH given subcutaneously once daily or bid is recommended over UFH , on an outpatient basis if possible , and as an inpatient if necessary [ 7 ] .", "label": "", "metadata": {}, "score": "51.486248"}
{"text": "Rivaroxaban .Two small phase II studies ( EINSTEIN - Dose and ODIXa ) looked at rivaroxaban in patients with acute deep vein thrombosis and were primarily concerned with imaging endpoints , though the endpoints of interest for our study were also reported .", "label": "", "metadata": {}, "score": "51.495724"}
{"text": "However , currently available unfractionated heparin assays are much more expensive than the aPTT , are not widely available , and their validity has not been adequately assessed in clinical outcome studies ... .", "label": "", "metadata": {}, "score": "51.497684"}
{"text": "[ 6 - 8 ] , as well as specialty - based VTE guidelines .Due to the number and complexity of indications in VTE management , the choice of antithrombotic agent can appear complicated .", "label": "", "metadata": {}, "score": "51.563877"}
{"text": "UFH has long been used as an anticoagulant in the prevention and treatment of VTE .Prophylaxis with anticoagulants is effective in reducing the incidence of VTE and in treating acute VTE [ 6 , 8 , 13 ] , but is inherently associated with a risk of bleeding complications .", "label": "", "metadata": {}, "score": "51.588665"}
{"text": "Key aspects ... .Bivalirudin demonstrated similar efficacy but resulted in a lower rate of bleeding compared to unfractionated heparin ( UFH ) plus platelet glycoprotein IIb / IIIa inhibitors in patients undergoing percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "51.603836"}
{"text": "View at Google Scholar \u00b7 View at Scopus . A. T. Cohen , B. L. Davidson , A. S. Gallus et al . , \" Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients : randomised placebo controlled trial , \" British Medical Journal , vol .", "label": "", "metadata": {}, "score": "51.613956"}
{"text": "PURPOSE : The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "51.702602"}
{"text": "Keywords .Vitamin K antagonists Oral anticoagulants Apixaban Rivaroxaban Dabigatran Orthopedic surgery Knee replacement Hip replacement Acute coronary syndrome Atrial fibrillation Venous thromboembolism Critically ill patients Systematic review .", "label": "", "metadata": {}, "score": "51.781986"}
{"text": "10.1067/mhj.2003.189 View Article PubMed .Hillbom M , Eril\u00e4 T , Sotaniemi K , Tatlisumak T , Sarna S , Kaste M : Enoxaparin vs heparin for prevention of deep - vein thrombosis in acute ischaemic stroke : a randomized , double - blind study .", "label": "", "metadata": {}, "score": "51.847298"}
{"text": "Despite a potentially complementary action of anticoagulant and antiplatelet drugs , the use of combination warfarin - ASA therapy is not based on compelling evidence of a net therapeutic benefit , with the exception of patients with a mechanical heart valve .", "label": "", "metadata": {}, "score": "51.84939"}
{"text": "Another study reported higher rates of bleeding and transfusions in patient with acute coronary syndrome that were prescribed unadjusted doses of antithrombotics based on CG [ 30 ] .", "label": "", "metadata": {}, "score": "51.94496"}
{"text": "Analyses were stratified by trial and included major bleeding as a time - varying covariate .In the final model , we used a Cox model to determine the effect of fondaparinux compared with control on mortality in those with and without major bleeding and performed a formal test for an interaction ( major bleeding ? fondaparinux ) .", "label": "", "metadata": {}, "score": "51.95781"}
{"text": "The magnitude of the reduction in major bleeding was less apparent for other novel oral anticoagulants and did not reach significance .Importantly , the sample sizes of the individual randomised controlled trials included in our meta - analysis were too small to provide reliable conclusions about the efficacy and safety of the novel oral anticoagulants .", "label": "", "metadata": {}, "score": "52.05705"}
{"text": "Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention .Despite the proven benefits , clear limitations of clopidogrel exist .", "label": "", "metadata": {}, "score": "52.15432"}
{"text": "We have summarized the findings of phase 3 trials on the new oral anticoagulants .A brief overview of the pharmacological properties of these agents is also presented .", "label": "", "metadata": {}, "score": "52.216618"}
{"text": "The differences in assay - responses become more pronounced at higher concentrations : for example , at prophylactic doses the anticoagulant levels of the branded and biosimilar enoxaparin appear similar but at treatment doses enoxaparin exhibits significantly greater anticoagulant effects [ 66 ] .", "label": "", "metadata": {}, "score": "52.28164"}
{"text": "In a randomized , placebo - controlled study of 16 healthy male subjects who received a single dose of fondaparinux ( 10 mg ) , the effect of a single dose of 90 \u03bc /kg intravenous ( IV ) bolus of rFVIIa was studied on coagulation parameters .", "label": "", "metadata": {}, "score": "52.33982"}
{"text": "The limitations of existing oral and parenteral anticoagulants have prompted a search for novel agents .As new drug targets are identified and potent inhibitors are developed , the validity of these targets requires testing in well - designed clinical trials .", "label": "", "metadata": {}, "score": "52.351532"}
{"text": "Les mesures d'h\u00e9mostase locales ou locor\u00e9gionales , lorsqu'elles sont possibles , sont un \u00e9l\u00e9ment essentiel du traitement des accidents h\u00e9morragiques .[ Show abstract ] [ Hide abstract ] ABSTRACT : Apixaban is a direct inhibitor of coagulation factor Xa .", "label": "", "metadata": {}, "score": "52.49479"}
{"text": "In phase 2 clinical trials , apixaban has been shown to provide effective and predictable anticoagulation over the doses of 5 , 10 or 20 mg / day in the prevention and treatment of venous thromboembolism [ 5 , 6 ] .", "label": "", "metadata": {}, "score": "52.537544"}
{"text": "These profiles were clustered using a between subject model mixture with interoccasion variability .The concomitant administration of PPI did not significantly change dabigatran pharmacokinetics .", "label": "", "metadata": {}, "score": "52.658607"}
{"text": "As these agents become more commonly used in clinical practice , it is imperative for the physicians to be aware of their pharmacological properties .Also , the future studies should attempt to identify effective reversal agents to be used in case of an adverse effect , such as a major bleed .", "label": "", "metadata": {}, "score": "52.66349"}
{"text": "10.1001/archinte.160.14.2199 View Article PubMed .Plan\u00e8s A , Samama MM , Lensing AW , B\u00fcller HR , Barre J , Vochelle N , Beau B : Prevention of deep vein thrombosis after hip replacement -- comparison between two low - molecular heparins , tinzaparin and enoxaparin .", "label": "", "metadata": {}, "score": "52.692513"}
{"text": "10.1002/bjs.1800840817 View Article .Br J Surg 1995 , 82 : 496 - 501 .10.1002/bjs.1800820421 View Article PubMed .Agnelli G , Bergqvist D , Cohen AT , Gallus AS , Gent M , PEGASUS investigators : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high - risk abdominal surgery .", "label": "", "metadata": {}, "score": "52.761086"}
{"text": "Therefore the adjusted indirect comparison was performed only between rivaroxaban and dabigatran .We used the R statistical software system v2.15.0 with the meta ( v2.0.1 ) package for statistical analysis . 8 9 Certain endpoints of potential interest were reported inconsistently between studies so pooling of data was not appropriate .", "label": "", "metadata": {}, "score": "52.811478"}
{"text": "First , we are unable to clarify whether there might be a causal relationship between less severe episodes of major bleeding and mortality .Second , participants included in the integrated fondaparinux database were those eligible for clinical trials and may not represent consecutive patients in real - life clinical practice .", "label": "", "metadata": {}, "score": "52.87063"}
{"text": "10.1046/j.0007 - 1323.2001.01800.x View Article PubMed .Turpie AG , Levine MN , Hirsh J , Carter CJ , Jay RM , Powers PJ , Andrew M , Hull RD , Gent M : A randomized controlled trial of a low - molecular - weight heparin ( enoxaparin ) to prevent deep - vein thrombosis in patients undergoing elective hip surgery .", "label": "", "metadata": {}, "score": "52.977623"}
{"text": "Anticoagulation for venous thromboembolism .John W Eikelboom BMJ 334:645 .Will prasugrel supersede clopidogrel for acute coronary syndromes ?Graeme J Hankey Med J Aust 188:381 - 2 .", "label": "", "metadata": {}, "score": "52.98304"}
{"text": "4 , pp .762 - 769 , 2009 .View at Publisher \u00b7 View at Google Scholar .B. L. Davidson , H. R. B\u00fcller , H. Decousus et al . , \" Effect of obesity on outcomes after fondaparinux , enoxaparin , or heparin treatment for acute venous thromboembolism in the Matisse trials , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "53.032356"}
{"text": "They were found to be non - inferior to the conventional treatment , but also seem to be associated with a decreased risk of major bleeding , in a quite young and without significant comorbidities population .", "label": "", "metadata": {}, "score": "53.062954"}
{"text": "In this review , we explore the potential mechanisms as well as the implications of these organ - specific bleeding patterns .The effect of homocysteine - lowering with B - vitamins on osteoporotic fractures in patients with cerebrovascular disease : substudy of VITATOPS , a randomised placebo - controlled trial .", "label": "", "metadata": {}, "score": "53.120777"}
{"text": "It has been shown that bleeding complications are associated with higher mortality rates among patients undergoing coronary angioplasty .Due to its properties , bivalirudin may provide benefits in terms of bleeding and thrombotic complications as compared to unfractionated heparin ( UFH ) .", "label": "", "metadata": {}, "score": "53.185482"}
{"text": "10 , pp .1212 - 1220 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . H. R. B\u00fcller , B. L. Davidson , H. Decousus et al . , \" Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vienous thrombosis : a randomized trial , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "53.26172"}
{"text": "BACKGROUND : Recent data suggests that low molecular weight heparins ( LMWHs ) may be superior to unfractionated heparin ( UFH ) as an adjunct to fibrinolytic therapy in patients with acute ST - segment elevation myocardial infarction ( STEMI ) .", "label": "", "metadata": {}, "score": "53.36898"}
{"text": "Stangier J , St\u00e4hle H , Rathgen K , Reseski K , K\u00f6rnicke T : Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [ abstract].", "label": "", "metadata": {}, "score": "53.38218"}
{"text": "It is metabolized in the liver and must be used with caution in patients with hepatic dysfunction .Argatroban is licensed for the treatment of heparin - induced thrombocytopenia .", "label": "", "metadata": {}, "score": "53.394836"}
{"text": "Therefore , when prescribing a LMWH for either the prevention or treatment of VTE , the clinical evidence for each agent must be reviewed .This review aims to assist this decision - making process by analyzing points of differentiation between each of the parenteral antithrombotic agents recommended in current VTE management guidelines .", "label": "", "metadata": {}, "score": "53.418198"}
{"text": "ASCO recommends using therapeutic anticoagulation in cancer patients with preexisting thrombocytopenia with caution .Validated bleeding assessment tools in the literature are evolving .The prospective registry Registro Informatizado de La Enfermedad Thromboemb\u00f3lic\u00e0 ( RIETE ) investigators have identified variables such as recent major bleed , renal dysfunction , anemia , cancer , clinically overt PE , and advanced age as being associated with major bleeding .", "label": "", "metadata": {}, "score": "53.426353"}
{"text": "Discussion .This systematic review , meta - analysis , and adjusted indirect comparison of the novel oral anticoagulants compared with vitamin K antagonists for the treatment of acute venous thromboembolism showed no significant differences in the risk of recurrence and the risk of all cause mortality .", "label": "", "metadata": {}, "score": "53.447865"}
{"text": "10.1007/s11239 - 005 - 1848-x View Article PubMed .Mismetti P , Quenet S , Levine M , Merli G , Decousus H , Derobert E , Laporte S : Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism : an individual patient data meta - analysis .", "label": "", "metadata": {}, "score": "53.475212"}
{"text": "The drug is excreted unchanged in the urine .Fondaparinux donot interact with protamine sulfate , the antidote for heparin .If uncontrolled bleeding occurs with fondaparinux , a procoagulant such as recombinant factor VIIa might be effective .", "label": "", "metadata": {}, "score": "53.634262"}
{"text": "There was a consistent pattern of reduced mortality with fondaparinux compared with control in both the pres- ence and absence of major bleeding , with no statistical evidence of heterogeneity between the 2 groups .", "label": "", "metadata": {}, "score": "53.66996"}
{"text": "Role of Factor XaInhibitors in Cancer - Associated Thrombosis : Any New Data ?Received 21 July 2011 ; Revised 10 August 2011 ; Accepted 11 August 2011 .", "label": "", "metadata": {}, "score": "53.726826"}
{"text": "A large clustered randomized controlled trial is , however , needed to assess whether early , multimodality , universal VTE prophylaxis can improve important clinical outcomes of hospitalized elderly patients .", "label": "", "metadata": {}, "score": "53.74301"}
{"text": "In patients undergoing abdominal or pelvic surgery for cancer , enoxaparin 40 mg once daily was as effective and safe as UFH administered tid [ 31 ] .", "label": "", "metadata": {}, "score": "53.77483"}
{"text": "Accordingly , LMWHs have a much greater inhibitory effect on Factor Xa than on thrombin .Whereas UFH has an anti - Factor Xa to anti - Factor IIa ratio of 1:1 , the corresponding ratio for the LMWHs ranges from 2:1 to 14:1 .", "label": "", "metadata": {}, "score": "53.794823"}
{"text": "These results need further investigation in forthcoming idraparinux trials .Currently , one case report of successful reversal of idraparinux with rVIIa ( 30 \u03bc g / kg ) exists in the literature [ 73 ] .", "label": "", "metadata": {}, "score": "53.801674"}
{"text": "MEDLINE and EMBASE databases were searched to identify relevant original articles .Results .Low - molecular - weight heparins have nearly replaced unfractionated heparin as the gold standard antithrombotic agent .", "label": "", "metadata": {}, "score": "53.854313"}
{"text": "Haemostasis 1996 , 26(Suppl 2):49 - 56 .PubMed .Kleber FX , Witt C , Vogel G , Koppenhagen K , Schomaker U , Flosbach CW , THE - PRINCE Study Group : Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease .", "label": "", "metadata": {}, "score": "53.875443"}
{"text": "Tinzaparin is licensed for the treatment of VTE but not for VTE prophylaxis in any patient group , while dalteparin is licensed for VTE prevention but not for VTE treatment other than long - term treatment in cancer patients .", "label": "", "metadata": {}, "score": "53.896294"}
{"text": "The use of antithrombotic agents in VTE management spans a continuum ranging from VTE prevention using prophylaxis of appropriate duration for at - risk patients to timely treatment of VTE .", "label": "", "metadata": {}, "score": "53.90488"}
{"text": "3 These agents have been extensively studied for prophylaxis of acute venous thromboembolism , long term anticoagulation for atrial fibrillation , and acute coronary syndromes .", "label": "", "metadata": {}, "score": "53.931824"}
{"text": "10.1056/NEJM199603143341101 View Article PubMed .Arch Intern Med 2005 , 165 : 733 - 738 .10.1001/archinte.165.7.733 View Article PubMed .Dolovich LR , Ginsberg JS , Douketis JD , Holbrook AM , Cheah G : A meta - analysis comparing low - molecular - weight heparins with unfractionated heparin in the treatment of venous thromboembolism : examining some unanswered questions regarding location of treatment , product type , and dosing frequency .", "label": "", "metadata": {}, "score": "53.93958"}
{"text": "Novel findings .As far as we know , this study is the first overall analysis of the novel oral anticoagulants for treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "54.100594"}
{"text": "14 , pp .1575 - 1596 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. J. Rupprecht and R. Blank , \" Clinical pharmacology of direct and indirect factor xa inhibitors , \" Drugs , vol .", "label": "", "metadata": {}, "score": "54.200462"}
{"text": "In patients with a history of HIT Fondaparinux seems to be effective and safe ; however , controlled clinical trials are necessary to confirm our observations .", "label": "", "metadata": {}, "score": "54.20456"}
{"text": "The thienopyridine clopidogrel is accepted as a key component of antiplatelet management and is recommended ... .Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting ( CABG ) after non - ST elevation myocardial infarctions .", "label": "", "metadata": {}, "score": "54.35305"}
{"text": "10.1016/S0140 - 6736(96)01453 - 5 View Article PubMed .Bergqvist D , Benoni G , Bj\u00f6rgell O , Fredin H , Hedlundh U , Nicolas S , Nilsson P , Nylander G : Low - molecular - weight heparin ( enoxaparin ) as prophylaxis against venous thromboembolism after total hip replacement .", "label": "", "metadata": {}, "score": "54.378304"}
{"text": "10.1124/dmd.108.023143 View Article PubMed .Eriksson BI , Quinlan DJ , Weitz JI : Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development .", "label": "", "metadata": {}, "score": "54.38336"}
{"text": "Symptomatic venous thromboembolism .In the RE - COVER 1 trial [ 52 ] , patients with acute venous thromboembolism were randomized double - blind to six months of treatment with either dabigatran 150 mg twice daily or warfarin that was dose - adjusted to achieve an INR of 2.0 to 3.0 after initial treatment with a parenteral anticoagulant .", "label": "", "metadata": {}, "score": "54.42959"}
{"text": "10.1056/NEJMoa0810773 View Article PubMed .Lassen MR , Raskob GE , Gallus A , Pineo G , Chen D , Hornick P : Apixaban versus enoxaparin for thromboprophylaxis after knee replacement ( ADVANCE-2 ) : a randomised double - blind trial .", "label": "", "metadata": {}, "score": "54.452"}
{"text": "Similarly , the drug significantly reduced the incidence of VTE in patients of total knee arthroplasty when compared with placebo while the rates of bleeding were similar in both groups [ 34 ] .", "label": "", "metadata": {}, "score": "54.474297"}
{"text": "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin : results from the Randomized Evaluation of Long - Term Anticoagulation Therapy ( RE - LY ) randomized trial .", "label": "", "metadata": {}, "score": "54.550045"}
{"text": "VKAs can be reversed with administration of vitamin K , LMWH can be partially reversed with the administration of protamine , and UFH can be completely reversed with administration of protamine ; in bleeding events , transfusion of red blood cells is required as well [ 62 ] .", "label": "", "metadata": {}, "score": "54.653557"}
{"text": "In the absence of trials making head to head comparisons between novel oral anticoagulants , we performed an adjusted indirect comparison using a single common comparator - that is , vitamin K antagonists - using the Bucher technique .", "label": "", "metadata": {}, "score": "54.66172"}
{"text": "As well as novel oral anticoagulant agents , biosimilar and/or generic low - molecular - weight heparins are now commercially available .Despite similar anticoagulant properties , studies report differences between the branded and biosimilar and/or generic agents and further clinical studies are required to support the use of biosimilar low - molecular - weight heparins .", "label": "", "metadata": {}, "score": "54.680172"}
{"text": "In this review , we have summarized the evidence from phase 3 clinical trials pertaining to the efficacy of apixaban , rivaroxaban , edoxaban and dabigatran in commonly encountered clinical conditions such as acute coronary syndrome , atrial fibrillation , symptomatic venous thromboembolism and orthopedic surgery .", "label": "", "metadata": {}, "score": "54.683567"}
{"text": "The association between cancer and venous thromboembolism ( VTE ) has been well documented in the literature .Prevention and treatment of VTE in cancer patients is imperative .", "label": "", "metadata": {}, "score": "54.74745"}
{"text": "Aspirin decreases the risk of cardiovascular events in patients with prior coronary heart or cerebrovascular disease .The American ... .BACKGROUND :Currently recommended anticoagulant agents used in the setting of percutaneous coronary intervention ( PCI ) inhibit , with varying degrees of intensity , 2 critical targets ( factor Xa and/or IIa ) of the coagulation cascade , yet they carry significant limitations .", "label": "", "metadata": {}, "score": "54.835938"}
{"text": "The other high - molecular - weight chains with low anticoagulant properties exhibit protein- and cell - binding effects and contribute to bleeding and other side - effects of UFH , such as thrombocytopenia and osteopenia [ 14 ] .", "label": "", "metadata": {}, "score": "54.863914"}
{"text": "PubMed .Simmoneau G , Sors H , Charbonnier B , Page Y , Laaban JP , Azarian R , Laurent M , Hirsch JL , Ferrari E , Bosson JL , Mottier D , Beau B : A comparison of low - molecular - weight heparin with unfractionated heparin for acute pulmonary embolism .", "label": "", "metadata": {}, "score": "54.866814"}
{"text": "Indirect inhibitors act by catalyzing factor Xa inhibition by antithrombin .In contrast , direct factor Xa inhibitors bind directly to the active site of factor Xa , thereby blocking its interaction with its substrates .", "label": "", "metadata": {}, "score": "54.888252"}
{"text": "Thromboembolic ( TE ) disease is a common cause of morbidity and mortality .Vitamin K antagonists ( VKAs ) such as warfarin are traditionally used for the prolonged management of thromboembolic disease .", "label": "", "metadata": {}, "score": "54.962875"}
{"text": "10.1056/NEJMoa1110899 View Article PubMed .Lassen MR , Raskob GE , Gallus A , Pineo G , Chen D , Portman RJ : Apixaban or enoxaparin for thromboprophylaxis after knee replacement .", "label": "", "metadata": {}, "score": "54.999546"}
{"text": "This therapy consists of unfractionated heparin ( UFH ) , low - molecular - weight heparin ( LMWH ) , factor Xa inhibitor , or vitamin K antagonist ( VKA ) .", "label": "", "metadata": {}, "score": "55.235607"}
{"text": "Three patients in the idrabiotaparinux group required avidin for planned procedures with favorable outcomes [ 74 ] .Overall results showed the comparative efficacy and safety of idrabiotaparinux to idraparinux .", "label": "", "metadata": {}, "score": "55.28986"}
{"text": "Herbert JM , H\u00e9rault JP , Bernat A , van Amsterdam RG , Lormeau JC , Petitou M , van Boeckel C , Hoffmann P , Meuleman DG : Biochemical and pharmacological properties of SANORG 34006 , a potent and long - acting synthetic pentasaccharide .", "label": "", "metadata": {}, "score": "55.335297"}
{"text": "A simple way to overcome this problem is to implement universal VTE prophylaxis for all hospitalized elderly patients instead of selective prophylaxis for some patients only according to individual 's risk of VTE .", "label": "", "metadata": {}, "score": "55.377174"}
{"text": "Inhibitors of fibrin formation : .Inhibitors of fibrin formation Direct thrombin inhibitors include Hirudin ( refludan and lepirudine ) and its derivatives bivalirudine , agatroban , ximelagatran and dabigatran .", "label": "", "metadata": {}, "score": "55.501316"}
{"text": "Meta - analyses of randomized controlled clinical studies have shown that the LMWHs are at least as safe and effective as UFH in preventing VTE in both medical and surgical inpatients [ 16 , 17 ] .", "label": "", "metadata": {}, "score": "55.600845"}
{"text": "In addition , along with a rapid onset and offset of action , these agents have low potential for dietary interactions .As a result , the new oral agents are more convenient to administer than warfarin and therefore may limit the long term use of warfarin .", "label": "", "metadata": {}, "score": "55.659935"}
{"text": "10.1378/chest.128.4.2203 View Article PubMed .Huse DM , Cummins G , Taylor DC , Russell MW : Outpatient treatment of venous thromboembolism with low - molecular - weight heparin : an economic evaluation .", "label": "", "metadata": {}, "score": "55.683823"}
{"text": "Incidence of major bleeding was 1.4 % per year in the apixaban group whereas 1.2 % in the aspirin group .Acute coronary syndrome .To compare apixaban versus standard antiplatelet therapy in patients with acute coronary syndrome ( ACS ) with at least two risk factors for recurrent ischemia , the Apixaban for Prevention of Acute Ischemic Events 2 ( APPRAISE-2 ) [ 14 ] trial was conducted .", "label": "", "metadata": {}, "score": "55.72252"}
{"text": "Thromb Haemost 2011 , 105(3):535 - 544 .View Article PubMed .Mendell J , Tachibana M , Shi M , Kunitada S : Effects of food on the pharmacokinetics of edoxaban , an oral direct factor Xa inhibitor , in healthy volunteers .", "label": "", "metadata": {}, "score": "55.725945"}
{"text": "Patients with atrial fibrillation ( AF ) are at increased risk of stroke .Betrixaban is a novel oral factor Xa inhibitor administered once daily , mostly excreted unchanged in the bile and with low ( 17 % ) renal excretion ... .", "label": "", "metadata": {}, "score": "55.733475"}
{"text": "Cancer patients have a 4-fold higher risk of developing VTE than do patients without cancer , and chemotherapy increases that risk to 6-fold [ 2 ] .", "label": "", "metadata": {}, "score": "55.813602"}
{"text": "PubMed .Mismetti P , Laporte S , Darmon JY , Buchm\u00fcller A , Decousus H : Meta - analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery .", "label": "", "metadata": {}, "score": "55.970234"}
{"text": "The protease - activated receptor 1 ( PAR-1 ) , the main platelet receptor for thrombin , represents a novel target for treatment of arterial thrombosis , and SCH 530348 is an orally active , selective , competitive PAR-1 antagonist .", "label": "", "metadata": {}, "score": "55.974457"}
{"text": "After the initial feasibility studies [ 27 , 28 ] the EINSTEIN clinical trials program was initiated to test the efficacy of rivaroxaban as a single agent for the management of symptomatic VTE .", "label": "", "metadata": {}, "score": "56.019825"}
{"text": "Among patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment , an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo .", "label": "", "metadata": {}, "score": "56.05748"}
{"text": "In this review , we attempt to provide a balanced perspective on the relative merits and demerits of the new , orally active anticoagulants , and speculate on the future of these agents in clinical practice ... .", "label": "", "metadata": {}, "score": "56.071"}
{"text": "OBJECTIVES :We used a U.S. model of health care costs to examine the cost effectiveness of enoxaparin compared with unfractionated heparin ( UFH ) as adjunctive therapy for fibrinolysis in patients with ST - segment elevation myocardial infarction ( STEMI ) .", "label": "", "metadata": {}, "score": "56.123665"}
{"text": "Co- administration of dabigatran with atorvastatin ( a substrate for CYP3A4 and P - glycoprotein ) [ 40 ] , digoxin ( a P - glycoprotein substrate ) [ 41 ] or diclofenac ( a CYP2C9 substrate ) [ 42 ] did not result in clinically relevant drug interactions .", "label": "", "metadata": {}, "score": "56.134308"}
{"text": "Guidelines for the management of acute coronary syndromes 2006 .John W Eikelboom Med J Aust 186:101 ; discussion 101 - 2 .Aspirin resistance .", "label": "", "metadata": {}, "score": "56.221115"}
{"text": "Effective thromboprophylaxis can minimize mortality and morbidity , potentially affect survival , and lower health - care costs associated with VTE .The National Comprehensive Cancer Network ( NCCN ) , the American Society of Clinical Oncology ( ASCO ) , and recently the American College of Chest Physicians ( ACCP ) have published guidelines for the prevention and treatment of VTE in cancer patients ( Table 1 ) .", "label": "", "metadata": {}, "score": "56.244354"}
{"text": "A prespecified sensitivity analysis by drug class suggested that the strength of relationship might differ between pharmacological groups .However , the association was no longer detectable after adjustment for low - density lipoprotein cholesterol for statins or exclusion of open trials for niacin .", "label": "", "metadata": {}, "score": "56.290318"}
{"text": "N Engl J Med .CLINICAL PERSPECTIVE Patients receiving antithrombotic therapy for the treatment of acute coronary syndrome who develop major bleeding are at increased risk of nonfatal and fatal cardiovascular outcomes compared with those who do not develop bleeding .", "label": "", "metadata": {}, "score": "56.370342"}
{"text": "Thrombin potently activates platelets via interaction with the protease - activated receptor 1 .SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease - activated receptor 1 .", "label": "", "metadata": {}, "score": "56.44354"}
{"text": "Smogorzewska et al . showed that fondaparinux ( prophylactic or therapeutic dose ) prolonged PT by 1 second and the aPTT by 4 to 5 seconds without significant changes in fibrinogen , AT , and thrombin time assays [ 39 ] .", "label": "", "metadata": {}, "score": "56.455894"}
{"text": "View at Google Scholar \u00b7 View at Scopus .F. Huvers , R. Slappendel , B. Benraad , G. van Hellemondt , and M. van Kraaij , \" Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid , \" The Netherlands Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "56.465378"}
{"text": "Idraparinux binds antithrombin with such high affinity that its plasma half - life of 130 h is similar to that of antithrombin .Because of its long half - life , idraparinux can be given subcutaneously on a once - weekly basis .", "label": "", "metadata": {}, "score": "56.551613"}
{"text": "This study sought to evaluate procedural major bleeding and myocardial infarction in patients undergoing stent implantation with adjunctive ... .Antiplatelet therapy is the cornerstone of management in acute coronary syndromes ( ACS ) and percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "56.664436"}
{"text": "On the other hand , the EMEA has considered these agents to be biosimilar .Furthermore , the EMEA stated that biosimilar versions of LMWHs should be considered biological medicinal products and may not be submitted for approval as generic medicinal products .", "label": "", "metadata": {}, "score": "56.66885"}
{"text": "Low - molecular - weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism : a meta - analysis of randomized , controlled trials .", "label": "", "metadata": {}, "score": "56.697525"}
{"text": "In everyday practice , clinicians should combine the best available evidence with clinical judgment , considering that in most clinical scenarios , clinical practice guideline may not provide clear recommendations for patients who should , and should not , receive combination warfarin - ASA therapy .", "label": "", "metadata": {}, "score": "56.740093"}
{"text": "This is first study , to our knowledge , to demonstrate that major bleeding is associated with an increase in mortality in the VTE prevention population .", "label": "", "metadata": {}, "score": "56.74613"}
{"text": "Bivalirubin has been approved by the United states Food and Drug Administration for use in patients with unstable angina in patients undergoing percutaneous cornary intervention .", "label": "", "metadata": {}, "score": "56.956543"}
{"text": "10 , pp .1142 - 1145 , 2004 .View at Google Scholar \u00b7 View at Scopus .L. A. Linkins , J. A. Julian , J. Rischke , J. Hirsh , and J. I. Weitz , \" In vitro comparison of the effect of heparin , enoxaparin and fondaparinux on tests of coagulation , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "57.11708"}
{"text": "Many issues remain to be elucidated , such as long - term safety , drug initiation , reversal of anticoagulation , and the appropriate bridging protocol from parenteral agents .", "label": "", "metadata": {}, "score": "57.16726"}
{"text": "5 , pp .999 - 1000 , 2005 .View at Google Scholar \u00b7 View at Scopus .J. P. J. Wester , A. Leyte , H. M. Oudemans - van Straaten et al . , \" Low - dose fondaparinux in suspected heparin - induced thrombocytopenia in the critically ill , \" The Netherlands Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "57.221397"}
{"text": "LMWH has been shown to bind mostly to factor Xa and minimally to factor IIa through activation of antithrombin ( AT ) III ( ATIII ) [ 12 ] .", "label": "", "metadata": {}, "score": "57.28255"}
{"text": "10.1177/0091270010370974 View Article PubMed .Raskob G , Cohen AT , Eriksson BI , Puskas D , Shi M , Bocanegra T , Weitz JI : Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement .", "label": "", "metadata": {}, "score": "57.37367"}
{"text": "Only about one - third of the heparin molecules contain the pentasaccharide binding sequence required for its anticoagulant effect .By binding to AT , heparin induces a conformational change that facilitates the binding of AT to thrombin and catalyzes the inhibitory action of AT on both thrombin and Factor Xa .", "label": "", "metadata": {}, "score": "57.447895"}
{"text": "10.1111/j.1538 -7836.2007.02764.x View Article PubMed .Ogawa S , Shinohara Y , Kanmuri K : Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non - valvular atrial fibrillation .", "label": "", "metadata": {}, "score": "57.45481"}
{"text": "Jeske WP , Brubaker A , Hoppensteadt D , Walenga JM , Ma Q , Fareed J : Differences in the oligosaccharide composition of generic versions of enoxaparin and dalteparin [ abstract].", "label": "", "metadata": {}, "score": "57.507423"}
{"text": "Dabigatran is a new oral direct thrombin inhibitor ... .Causes of death and influencing factors in patients with atrial fibrillation : a competing - risk analysis from the randomized evaluation of long - term anticoagulant therapy study .", "label": "", "metadata": {}, "score": "57.527054"}
{"text": "Lindmarker P , Holmstr\u00f6m M , Granqvist S , Johnsson H , Lockner D : Comparison of once - daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis .", "label": "", "metadata": {}, "score": "57.68708"}
{"text": "10.1056/NEJM199609053351002 View Article PubMed .Comp PC , Spiro TE , Friedman RJ , Whitsett TL , Johnson GJ , Gardiner GA Jr , Landon GC , Jov\u00e9 M , Enoxaparin Clinical Trial Group : Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement .", "label": "", "metadata": {}, "score": "57.729736"}
{"text": "[ Epub ahead of print ] .Schulman S , Kearon C , Kakkar AK , Mismetti P , Schellong S , Eriksson H , Baanstra D , Schnee J , Goldhaber SZ : Dabigatran versus warfarin in the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "57.778763"}
{"text": "101 - 108 , 2007 .View at Google Scholar \u00b7 View at Scopus .K. A. Alsaleh , S. M. A. Al - Nasser , S. M. Bates , A. Patel , T. E. Warkentin , and D. M. Arnold , \" Delayed - onset HIT caused by low - molecular - weight heparin manifesting during fondaparinux prophylaxis , \" American Journal of Hematology , vol .", "label": "", "metadata": {}, "score": "57.79827"}
{"text": "The anticoagulant effect of hirudin can be monitored using the activated partial thromboplastin time ( APTT ) .Direct Thrombin Inhibitors : .Slide 15 : .", "label": "", "metadata": {}, "score": "57.81846"}
{"text": "A meta - analysis of studies of enoxaparin outpatient treatment including more than 1,500 patients with DVT , with or without PE , reported that enoxaparin is as effective in terms of VTE recurrence , major bleeding , and death as inpatient treatment with UFH [ 62 ] .", "label": "", "metadata": {}, "score": "57.871357"}
{"text": "16 , pp .2153 - 2170 , 2010 .View at Google Scholar \u00b7 View at Scopus . F. Donat , J. P. Duret , A. Santoni et al . , \" The pharmacokinetics of fondaparinux sodium in healthy volunteers , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "57.96962"}
{"text": "Use of pharmacological agents for DVT prophylaxis in ICU patients should be based on evidence , the half - life of the agent , and the availability of an antidote if bleeding occurs .", "label": "", "metadata": {}, "score": "58.1771"}
{"text": "In one study , risk of bleeding associated with anticoagulation in cancer patients was about 4.2 % during 90 days of therapy , with a mortality rate greater than 60 % within 30 days of a major bleeding event [ 58 ] .", "label": "", "metadata": {}, "score": "58.19156"}
{"text": "Further investigation is required to understand the determinants of major bleeding and the mechanism of in- creased mortality in patients who experience major bleeding while receiving VTE prophylaxis .", "label": "", "metadata": {}, "score": "58.283165"}
{"text": "J Thromb Haemost .Eriksson BI , Borris LC , Dahl OE , Haas S , Huisman MV , Kakkar AK , Muehlhofer E , Dierig C , Misselwitz F , Kalebo P. A once - daily , oral , direct factor Xa inhibitor , rivaroxaban ( BAY 59 - 7939 ) , for thrombo- prophylaxis after total hip replacement .", "label": "", "metadata": {}, "score": "58.43167"}
{"text": "17 Both patients who received dabigatran and those who received vitamin K antagonists received a full five day course of low molecular weight heparin before starting the study drug .", "label": "", "metadata": {}, "score": "58.565422"}
{"text": "The pharmacokinetic properties of drugs in ICU patients may be altered owing to reduced hepatic metabolism , reduced transport function , intestinal atrophy , increased or decreased extravascular fluids , reduced CrCl , altered tissue permeability , or decreased protein binding of the drugs [ 42 ] .", "label": "", "metadata": {}, "score": "58.60588"}
{"text": "10.1093/eurheartj / ehr113 View Article PubMed .Uchino K , Hernandez AV : Dabigatran association with higher risk of acute coronary events : metaanalysis of noninferiority randomized controlled trials .", "label": "", "metadata": {}, "score": "58.623882"}
{"text": "Trauma / surgery and previous acute venous thromboembolism were the most common associated risk factors described , though not all studies reported the same risk factors .", "label": "", "metadata": {}, "score": "58.63831"}
{"text": "John W Eikelboom Thromboembolism Unit , Hamilton General Hospital , Hamilton , Ontario , L8L 2X2 , Canada Circulation 120:2006 - 11 .Rationale and design of AVERROES : apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment .", "label": "", "metadata": {}, "score": "58.64141"}
{"text": "View Article PubMed .Mismetti P , Laporte - Simitsidis S , Tardy B , Cucherat M , Buchm\u00fcller A , Juillard - Delsart D , Decousus H : Prevention of venous thromboembolism in internal medicine with unfractionated or low - molecular - weight heparins : a meta - analysis of randomised clinical trials .", "label": "", "metadata": {}, "score": "58.641453"}
{"text": "PubMed .Fiessinger JN , Lopez - Fernandez M , Gatterer E , Granqvist S , Kher A , Olsson CG , S\u00f6derberg K : Once - daily subcutaneous dalteparin , a low molecular weight heparin , for the initial treatment of acute deep vein thrombosis .", "label": "", "metadata": {}, "score": "58.67665"}
{"text": "Stangier J , Clemens A : Pharmacology , pharmacokinetics , and pharmacodynamics of dabigatran etexilate , an oral direct thrombin inhibitor .Clin Appl Thromb Hemost 2009 , 15(Suppl 1):9S-16S. View Article PubMed .", "label": "", "metadata": {}, "score": "58.768433"}
{"text": "Dalteparin has also been evaluated for the prevention of VTE .In abdominal surgery , dalteparin 2,500 IU was as safe and effective as UFH bid [ 13 ] .", "label": "", "metadata": {}, "score": "58.77483"}
{"text": "10.2165/11318170 - 000000000 - 00000 View Article PubMed .Stangier J , Rathgen K , St\u00e4hle H , Reseski K , K\u00f6rnicke T , Roth W : Coadministration of dabigatran etexilate and atorvastatin : assessment of potential impact on pharmacokinetics and pharmacodynamics .", "label": "", "metadata": {}, "score": "58.988792"}
{"text": "Peak levels in 2 - 3 hours .Not protein bound .Half - life 3 - 4 hours .Eliminated via kidneys .Ximelagatran is being evaluated for thromboprophylaxis in high - risk orthopedic patients , for the treatment of venous thromboembolism , for the prevention of cardioembolic events in patients with nonvalvular atrial fibrillation .", "label": "", "metadata": {}, "score": "59.132626"}
{"text": "Major bleeding events were similar ( 0.6 % rivaroxaban vs. 0.5 % enoxaparin ) .These phase 3 trials showed comparable safety and superior efficacy of rivaroxaban compared with enoxaparin for thromboprophylaxis after hip or knee arthroplasty .", "label": "", "metadata": {}, "score": "59.164368"}
{"text": "Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention : results from the OASIS-5 trial .Shamir R Mehta Department of Medicine , McMaster University and Population Health Research Institute , Hamilton Health Sciences , Hamilton , Ontario , Canada J Am Coll Cardiol 50:1742 - 51 .", "label": "", "metadata": {}, "score": "59.38765"}
{"text": "22 Rivaroxaban was found to be superior to dabigatran , but there was a trend towards increased bleeding .Differences in therapeutic regimen and selection of patients could explain these discrepancies with our results .", "label": "", "metadata": {}, "score": "59.64283"}
{"text": "Rivaroxaban .In the large EINSTEIN studies there were fewer study discontinuations among patients randomised to rivaroxaban ( 10.7 - 11.3 % ) than among those randomised to vitamin K antagonists ( 12.3 - 14.2 % ) , driven by a high rate of withdrawal of consent in the vitamin K antagonists arm .", "label": "", "metadata": {}, "score": "59.681347"}
{"text": "Slide 16 : .Argatroban : A competitive inhibitor of thrombin , argatroban binds noncovalently to the active site of thrombin to form a reversible complex .", "label": "", "metadata": {}, "score": "59.685387"}
{"text": "To evaluate the efficacy and safety of retrievable vena cava filters plus anticoagulation vs anticoagulation alone for preventing pulmonary embolism recurrence in patients presenting with acute pulmonary embolism and a high risk of recurrence .", "label": "", "metadata": {}, "score": "59.744987"}
{"text": "These trials were limited in size and yielded inconclusive or conflicting results .Furthermore , the results have yet to be incorporated in a meta - analysis , which can reduce the amount of uncertainty surrounding the treatment effects .", "label": "", "metadata": {}, "score": "59.77888"}
{"text": "10.1177/1076029606291434 View Article PubMed .Jeske WP , Ackerman P , Drenth A , Walenga J , Bakhos M : Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays [ abstract].", "label": "", "metadata": {}, "score": "59.812973"}
{"text": "This was associated with an overall saving of USD 1,151 per patient in total DVT - treatment - related costs over warfarin monotherapy [ 63 ] .", "label": "", "metadata": {}, "score": "59.83849"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. C. Gosselin , J. H. King , K. A. Janatpur , W. H. Dager , E. C. Larkin , and J. T. Owings , \" Effects of pentasaccharide ( Fondaparinux ) and direct thrombin inhibitors on coagulation testing , \" Archives of Pathology and Laboratory Medicine , vol .", "label": "", "metadata": {}, "score": "59.863228"}
{"text": "However , the relatively low mortality may have hampered the conclusion of ... .OBJECTIVES :Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST - segment elevation myocardial infarction ( STEMI ) undergoing primary percutaneous coronary intervention ( PCI ) .", "label": "", "metadata": {}, "score": "59.898125"}
{"text": "Pharmacokinetic Profile .Fondaparinux is excreted via the kidneys ( 64 % to 74 % ) with a terminal half - life ( . )Fondaparinux is not metabolized by the cytochrome P450 ( CYP ) enzyme in the liver [ 15 ] .", "label": "", "metadata": {}, "score": "60.016808"}
{"text": "The direct and indirect costs of cardiovascular disease are estimated to surpass $ 165 billion in 2009 .Antiplatelet pharmacotherapy has been shown to ... .", "label": "", "metadata": {}, "score": "60.053402"}
{"text": "The oral bioavailability of this drug is approximately 6%-7 % , which is much lower than that of the other three oral anticoagulants [ 1 , 4 ] .", "label": "", "metadata": {}, "score": "60.189003"}
{"text": "Ageno W , Gallus AS , Wittkowsky A , Crowther M , Hylek EM , Palareti G , et al .Oral anticoagulant therapy : antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines .", "label": "", "metadata": {}, "score": "60.190964"}
{"text": "The main outcome measures were frequency of major bleeding , including haemorrhagic stroke , over time , ... .Low - molecular - weight heparin ( LMWH ) has been a mainstay for the management of acute coronary syndromes ( ACS ) for almost a decade .", "label": "", "metadata": {}, "score": "60.22502"}
{"text": "These findings do not support the use of this type of filter in patients who can be treated with anticoagulation .clinicaltrials.gov Identifier : NCT00457158 .", "label": "", "metadata": {}, "score": "60.255463"}
{"text": "Ann Intern Med 1991 , 114 : 545 - 551 .View Article PubMed .Colwell CW Jr , Spiro TE , Trowbridge AA , Morris BA , Kwaan HC , Blaha JD , Comerota AJ , Skoutakis VA : Use of enoxaparin , a low - molecular - weight heparin , and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement .", "label": "", "metadata": {}, "score": "60.371803"}
{"text": "The proportion of patients with reduced creatinine clearance in real life is expected to be substantially higher , and our findings may not be applicable to patients with severe renal impairment or those with other serious comorbidities .", "label": "", "metadata": {}, "score": "60.40542"}
{"text": "In the THRIVE II / V study , more patients were withdrawn in the ximelagatran arm of the study because of increased liver enzyme activity ( 10.2 % v 2.2 % for vitamin K antagonists ) .", "label": "", "metadata": {}, "score": "60.516624"}
{"text": "This study sought to determine the prevalence and predictors of pacemaker - detected AF and to document current oral anticoagulant use ... .New oral anticoagulants : not quite there yet .", "label": "", "metadata": {}, "score": "60.525925"}
{"text": "Non - inferiority for VTE recurrence and major bleeding was demonstrated compared to UFH in the treatment of PE [ 59 ] and compared to enoxaparin in the treatment of DVT [ 60 ] .", "label": "", "metadata": {}, "score": "60.591087"}
{"text": "B - vitamin supplements reduce tHcy and improve endothelial function in short term trials , but the long - term effects of the treatment on vascular structure and function are unknown ... .", "label": "", "metadata": {}, "score": "60.60415"}
{"text": "View Article PubMed .Prandoni P , Lensing AW , Piccioli A , Bernardi E , Simioni P , Girolami B , Marchiori A , Sabbion P , Prins MH , Noventa F , Girolami A : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis .", "label": "", "metadata": {}, "score": "60.60764"}
{"text": "10.1185/03007990802361499 View Article PubMed .Kubitza D , Becka M , Voith B , Zuehlsdorf M , Wensing G : Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor .", "label": "", "metadata": {}, "score": "60.654594"}
{"text": "There is uncertainty about the role of intravenous unfractionated heparin ( UFH ) and low - molecular - weight heparin ( LMWH ) in patients with ST - elevation myocardial infarction ( STEMI ) treated with aspirin and thrombolysis ... .", "label": "", "metadata": {}, "score": "60.664604"}
{"text": "6 , pp .454S-545S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .N. A. Reynolds , C. M. Perry , and L. J. Scott , \" Fondaparinux sodium : a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery , \" Drugs , vol .", "label": "", "metadata": {}, "score": "60.667347"}
{"text": "10.1056/NEJMoa1111096 View Article PubMed .Eriksson BI , Borris LC , Friedman RJ , Haas S , Huisman MV , Kakkar AK , Bandel TJ , Beckmann H , Muehlhofer E , Misselwitz F , Geerts W : Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty .", "label": "", "metadata": {}, "score": "60.670372"}
{"text": "Apixaban may be an attractive alternative to ASA for prevention of stroke in patients with AF who can not or will not take a VKA ... .", "label": "", "metadata": {}, "score": "60.69175"}
{"text": "Betrixaban compared with warfarin in patients with atrial fibrillation : results of a phase 2 , randomized , dose - ranging study ( Explore - Xa ) .", "label": "", "metadata": {}, "score": "60.8222"}
{"text": "Frequency of VTE has increased by up to 28 % in years 1995 to 2003 in hospitalized cancer patients and with the higher mortality rates compared to those hospitalized cancer patients without VTE ( 16.3 % versus 6.3 % , .", "label": "", "metadata": {}, "score": "60.88876"}
{"text": "10.1056/NEJMoa1105819 View Article PubMed .Kubitza D , Becka M , Roth A , Mueck W : Dose - escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects .", "label": "", "metadata": {}, "score": "60.890053"}
{"text": "N Engl J Med 2011 , 364(9):806 - 817 .10.1056/NEJMoa1007432 View Article PubMed . : Apixaban with antiplatelet therapy after acute coronary syndrome .", "label": "", "metadata": {}, "score": "60.910316"}
{"text": "10.1001/archinte.162.11.1245 View Article PubMed .Anderson FA Jr , Zayaruzny M , Heit JA , Fidan D , Cohen AT : Estimated annual numbers of US acute - care hospital patients at risk for venous thromboembolism .", "label": "", "metadata": {}, "score": "60.953705"}
{"text": "Dabigatran .The pivotal published study on dabigatran was RECOVER I , which enrolled patients with deep vein thrombosis and pulmonary embolism .16 This was a phase III non - inferiority , double blind , double dummy trial , which included sham monitoring of international normalised ratio and sham titration of vitamin K antagonists in the experimental group .", "label": "", "metadata": {}, "score": "60.95724"}
{"text": "In this subgroup analysis , higher rates of recurrent VTE during the entire study were observed in the UFH group compared with the fondaparinux group ( 17.2 % versus 8.9 % , . )", "label": "", "metadata": {}, "score": "60.983906"}
{"text": "References .Heit JA , O'Fallon WM , Petterson TM , Lohse CM , Silverstein MD , Mohr DN , Melton LJ : Relative impact of risk factors for deep vein thrombosis and pulmonary embolism : a population - based study .", "label": "", "metadata": {}, "score": "60.995037"}
{"text": "Dalteparin has been evaluated for extended - duration prophylaxis in surgical patients ; two double - blind placebo - controlled studies have shown a lower incidence of late VTE with dalteparin in patients undergoing total hip replacement surgery without increasing major bleeding [ 47 , 48 ] .", "label": "", "metadata": {}, "score": "61.01048"}
{"text": "Thrombin activates platelets , converts factor V to factor Va and factor VIII to factor VIIIa , and finally activates thrombin - activable fibrinolysis inhibitor ( TAFI ) , which downregulates fibrinolysis .", "label": "", "metadata": {}, "score": "61.01635"}
{"text": "Apixaban .Apixaban was associated with slightly increased rates of non - major bleeding ( 11 % v 8 % vitamin K antagonists ) and discontinuation ( 13 % v 8 % vitamin K antagonists ) .", "label": "", "metadata": {}, "score": "61.063156"}
{"text": "We performed a pilot study measuring safety and efficacy outcomes of aspirin and clopidogrel therapy after CABG ... .Exploratory studies on the age of transfused blood and in - hospital mortality in patients with cardiovascular diagnoses .", "label": "", "metadata": {}, "score": "61.081184"}
{"text": "More recently , the synthetic pentasaccharide fondaparinux has been developed and FDA approved .Mechanism of action .UFH is a heterogeneous mixture of highly sulfated mucopolysaccharides of varying lengths with molecular weights ranging from 3,000 to 30,000 Da ( mean 15,000 Da ) that has been used as an anticoagulant since the 1950s .", "label": "", "metadata": {}, "score": "61.12645"}
{"text": "The rates of primary efficacy outcome observed in this trial were consistent with those observed in REVOVATE I [ 45 ] .In the RE - MOBILIZE trial [ 48 ] of 1896 patients undergoing total knee arthroplasty , the North American enoxaparin regimen ( 30 mg BID postoperatively ) was used .", "label": "", "metadata": {}, "score": "61.19693"}
{"text": "Enoxaparin Clinical Trial Group .J Bone Joint Surg Am 1994 , 76 : 3 - 14 .PubMed .Colwell CW Jr , Collis DK , Paulson R , McCutchen JW , Bigler GT , Lutz S , Hardwick ME : Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty .", "label": "", "metadata": {}, "score": "61.201733"}
{"text": "PubMed .Bergqvist D , Agnelli G , Cohen AT , Eldor A , Nilsson PE , Le Moigne - Amrani A , Dietrich - Neto F , ENOXACAN II Investigators : Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer .", "label": "", "metadata": {}, "score": "61.207653"}
{"text": "10.1001/archinte.167.14.1471 PubMed Central View Article PubMed .Prandoni P , Lensing AW , Cogo A , Cuppini S , Villalta S , Carta M , Cattelan AM , Polistena P , Bernardi E , Prins MH : The long - term clinical course of acute deep venous thrombosis .", "label": "", "metadata": {}, "score": "61.26352"}
{"text": "Characteristics of an ideal anticoagulant are : Oral administration .Single daily dose .Predictable dose response and kinetics .High clinical efficacy .Low rate of complications .", "label": "", "metadata": {}, "score": "61.39595"}
{"text": "Januel JM , Chen G , Ruffieux C , Quan H , Douketis JD , Crowther MA , et al .Symptomatic in - hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis : a systematic review .", "label": "", "metadata": {}, "score": "61.428726"}
{"text": "Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST - segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug - eluting stents remains unclear .", "label": "", "metadata": {}, "score": "61.429497"}
{"text": "Two pivotal clinical trials MATISSE DVT and MATISSE PE have established the clinical efficacy and safety of the 7.5 mg daily therapeutic dose among patients whose body weight ranges between 50 and 100 kg .", "label": "", "metadata": {}, "score": "61.501656"}
{"text": "Finally , secondary outcomes such as minor bleeding and adverse events were not pooled , and we could not perform subgroup analysis according to the aetiology of acute venous thromboembolism because of the lack of patient level data .", "label": "", "metadata": {}, "score": "61.614815"}
{"text": "For this reason , the efficacy and safety data from the clinical studies for each LMWH need to be reviewed .Table 2 summarizes the key published data in the prevention of VTE for each of the LMWHs currently available in the USA and fondaparinux [ 13 , 19 - 40 ] .", "label": "", "metadata": {}, "score": "61.61521"}
{"text": "The recommended duration of treatment ranges from 3 to 12 months , depending on which set of guidelines is followed .For long - term treatment of VTE in cancer patients , guidelines do not address the role of factor Xa inhibitors [ 5 - 8 ] .", "label": "", "metadata": {}, "score": "61.695583"}
{"text": "References .Eikelboom JW , Weitz JI : New anticoagulants .Circulation 2010 , 121(13):1523 - 1532 .10.1161/CIRCULATIONAHA.109.853119 View Article PubMed .Altman R , Vidal HO : Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice ( the real world ) perspective .", "label": "", "metadata": {}, "score": "61.82155"}
{"text": "Both doses of dabigatran were therefore better than warfarin .Acute coronary syndrome .In patients with recent ST - elevation or non ST - elevation MI , dabigatran was given in addition to dual antiplatelet therapy in a double - blind , placebo - controlled , dose - escalation phase 2 ( RE - DEEM ) trial [ 50 ] .", "label": "", "metadata": {}, "score": "61.85916"}
{"text": "A recent meta - analysis reported the safety of rVIIa in randomized clinical trials .Levi et al . reported higher rates of arterial events ( mostly acute coronary syndrome ) in patients who received rVIIa than in patients who received a placebo ( 5.5 % versus 3.2 % ; OR : 1.68 , 95 % CI : 1.20 % to 2.36 % , . )", "label": "", "metadata": {}, "score": "61.889427"}
{"text": "To evaluate the cost - effectiveness of enoxaparin versus unfractionated heparin in conjunction with fibrinolysis in ST elevation myocardial infarction patients within Canada .Based on the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction ( ExTRACT - TIMI ) 25 trial , a model was created to analyze the cost - effectiveness of ... .", "label": "", "metadata": {}, "score": "61.937714"}
{"text": "Major bleeding occurred in 2.8 % of patients who received their first fondaparinux injection at least 6 hours after surgery closure and in 3.4 % of patients who received their first fondaparinux dose within 6 hours of surgery closure [ 23 ] .", "label": "", "metadata": {}, "score": "61.941605"}
{"text": "Thus there is a regulatory discordance between the EMEA and US FDA .As the biosimilar LMWHs have only recently been produced there is limited clinical data available with which to compare the biosimilar and branded versions .", "label": "", "metadata": {}, "score": "62.13449"}
{"text": "All forest plots for the secondary analysis are provided in the supplementary files .Adjusted indirect comparison .The adjusted indirect comparison was performed for active trial arms for rivaroxaban and dabigatran for each of the three endpoints .", "label": "", "metadata": {}, "score": "62.16149"}
{"text": "A total of 335 consecutive ... .Several randomized trials and a previous meta - analysis have shown significant benefits from Gp IIb - IIIa inhibitors , especially abciximab .", "label": "", "metadata": {}, "score": "62.21645"}
{"text": "Inhibitors of initiation of coagulation : .Inhibitors of initiation of coagulation Drugs that target the factor VIIa /tissue factor complex inhibit the initiation of coagulation .", "label": "", "metadata": {}, "score": "62.219795"}
{"text": "Several trials comparing enoxaparin 40 mg once daily or 30 mg bid with UFH bid or three times daily ( tid ) in this patient population demonstrated at least similar incidence rates of VTE and major bleeding [ 20 , 21 ] .", "label": "", "metadata": {}, "score": "62.283276"}
{"text": "Interestingly , investigators found no occurrence VTE and 2 minor bleeds with anti - Xa of 0.24 and 0.44 IU / mL [ 43 ] .", "label": "", "metadata": {}, "score": "62.28511"}
{"text": "Dabigatran reduces ischemic stroke in comparison with warfarin ; however , given the lack of antidote , there is concern that it might increase bleeding when surgery or invasive procedures are required ... .", "label": "", "metadata": {}, "score": "62.291626"}
{"text": "Each of the LMWHs is a distinct drug , with unique clinical pharmacokinetics and pharmacodynamics , and LMWHs can not be prescribed interchangeably .LMWHs should be prescribed in accordance with recommended dose regimens for each licensed clinical indication , based on the available clinical evidence for each agent .", "label": "", "metadata": {}, "score": "62.341686"}
{"text": "10.1056/NEJMoa1006885 View Article PubMed . : Apixaban versus warfarin in patients with atrial fibrillation .N Engl J Med 2011 , 365(11):981 - 992 .", "label": "", "metadata": {}, "score": "62.34857"}
{"text": "10.1007/BF03256595 View Article PubMed .Stangier J , St\u00e4hle H , Rathgen K , Reseski K , K\u00f6rnicke T : No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [ abstract].", "label": "", "metadata": {}, "score": "62.363945"}
{"text": "[ 33 ] Evidence suggests that bleeding from antithrombotic agents is a strong predictor of mortality and will reduce the overall benefits of VTE prophylaxis in hospitalized patients .", "label": "", "metadata": {}, "score": "62.37291"}
{"text": "Biosimilar versions of enoxaparin have been developed and being marketed as generic equivalents and clinically used in India and South America , and initial regulatory approval of a biosimilar formulation of enoxaparin was granted in Canada [ 65 ] .", "label": "", "metadata": {}, "score": "62.426758"}
{"text": "10.1016/j.ahj.2010.06.042 View Article PubMed .Blech S , Ebner T , Ludwig - Schwellinger E , Stangier J , Roth W : The metabolism and disposition of the oral direct thrombin inhibitor , dabigatran , in humans .", "label": "", "metadata": {}, "score": "62.434143"}
{"text": "5 , pp .241 - 244 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Smogorzewska , J. T. Brandt , W. L. Chandler et al . , \" Effect of fondaparinux on coagulation assays : results of College of American pathologists proficiency testing , \" Archives of Pathology and Laboratory Medicine , vol .", "label": "", "metadata": {}, "score": "62.47579"}
{"text": "Neither CG nor MDRD was accurate in the following patients : heart transplant patients , kidney donors , patients with advanced liver disease , and hospitalized patients [ 26 ] .", "label": "", "metadata": {}, "score": "62.475864"}
{"text": "Thus , dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI ... .", "label": "", "metadata": {}, "score": "62.600067"}
{"text": "We evaluated whether homocysteine - lowering therapy with B - vitamins in patients with symptomatic cerebrovascular disease reduced the incidence of osteoporotic fractures ... .Clinical update on the therapeutic use of clopidogrel : treatment of acute ST - segment elevation myocardial infarction ( STEMI ) .", "label": "", "metadata": {}, "score": "62.705353"}
{"text": "Bleeding Risk Assessment .To date , there is no validated bleeding risk assessment in cancer patients ; however , several bleeding assessment tools have been examined in clinical trials .", "label": "", "metadata": {}, "score": "62.73063"}
{"text": "10.1016/S0140 - 6736(09)62125 - 5 View Article PubMed .Lassen MR , Gallus A , Raskob GE , Pineo G , Chen D , Ramirez LM : Apixaban versus enoxaparin for thromboprophylaxis after hip replacement .", "label": "", "metadata": {}, "score": "62.813023"}
{"text": "We hypothesized that genetic variants could contribute to interindividual variability in blood concentrations of the active metabolite of dabigatran etexilate and influence the safety and efficacy of dabigatran ... .", "label": "", "metadata": {}, "score": "62.879528"}
{"text": "In primary prevention , aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced .", "label": "", "metadata": {}, "score": "62.913773"}
{"text": "10.1124/dmd.107.019083 View Article PubMed .Stangier J , Rathgen K , St\u00e4hle H , Mazur D : Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate .", "label": "", "metadata": {}, "score": "62.963657"}
{"text": "Conclusion .Considering their pharmacological properties , their efficacy and bleeding complications , the new oral agents offer a net favourable clinical profile in orthopedic surgery , atrial fibrillation , acute coronary syndrome and increase the risk of bleeding in critically ill patients .", "label": "", "metadata": {}, "score": "62.96985"}
{"text": "Finally , we adjusted our analyses for baseline characteristics , treatment allocation , and propensity for major bleeding that could confound the association with mortality .", "label": "", "metadata": {}, "score": "63.242977"}
{"text": "Kearon C , Akl EA , Comerota AJ , Prandoni P , Bounameaux H , Goldhaber SZ , et al .Antithrombotic therapy for VTE disease : antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines .", "label": "", "metadata": {}, "score": "63.277946"}
{"text": "Fondaparinux is considered a pentasaccharide and has an average molecular weight of 1.7 kDa and only 5 saccharide residue .Typically , in LMWHs , the range of molecular weight and saccharide residues vary from 4.5 kDa to 7.5 kDa and 13 to 15 saccharide residues , respectively .", "label": "", "metadata": {}, "score": "63.291702"}
{"text": "10.1056/NEJMoa0800374 View Article PubMed .Lancet 2008 , 372(9632):31 - 39 .10.1016/S0140 - 6736(08)60880 - 6 View Article PubMed .Lassen MR , Ageno W , Borris LC , Lieberman JR , Rosencher N , Bandel TJ , Misselwitz F , Turpie AG : Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty .", "label": "", "metadata": {}, "score": "63.501297"}
{"text": "Introduction .Venous thromboembolism is a common condition that is associated with considerable morbidity and mortality . 1 The mainstay of treatment has been initial use of parenteral anticoagulants followed by longer term use of oral vitamin K antagonists .", "label": "", "metadata": {}, "score": "63.504333"}
{"text": "S58-S61 , 2010 .View at Google Scholar \u00b7 View at Scopus .N. Ru\u00edz - Gim\u00e9nez , C. Su\u00e1rez , R. Gonz\u00e1lez , et al . , \" Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism .", "label": "", "metadata": {}, "score": "63.50451"}
{"text": "Dabigatran is another novel oral anticoagulant which has received recent approval in some European countries , Canada and recently in US ; dabigatran is a direct thrombin inhibitor , administered orally as a double prodrug formulation ( dabigatran etexilate ) .", "label": "", "metadata": {}, "score": "63.617184"}
{"text": "The CLOT trial reported that long - term prophylaxis with dalteparin in patients with cancer and DVT was associated with a significantly lower incidence of VTE recurrence compared to oral anticoagulant therapy with no increase in bleeding complications [ 64 ] .", "label": "", "metadata": {}, "score": "63.63603"}
{"text": "The recommended dose is 5 mg twice daily which can be reduced to 2.5 mg depending on the individual risk .Apixaban is also indicated for the treatment of venous thromboembolism but reimbursement has not yet been accepted in France for this indication .", "label": "", "metadata": {}, "score": "63.66471"}
{"text": "Orthopedic surgery .On the basis of the results of phase 2 studies demonstrating that dabigatran is effective for the prevention of venous thromboembolism ( VTE ) , phase 3 studies for thromboprophylaxis after hip or knee arthroplasty were conducted .", "label": "", "metadata": {}, "score": "63.902752"}
{"text": "1854 - 1861 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .G. Agnelli , D. Bergqvist , A. T. Cohen , A. S. Callus , and M. Gent , \" Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high - risk abdominal surgery , \" British Journal of Surgery , vol .", "label": "", "metadata": {}, "score": "63.941593"}
{"text": "10.2165/00002018 - 200831010 - 00006 View Article PubMed .Cohen AT , Spiro TE , B\u00fcller HR , Haskell L , Hu D , Hull R , Mebazaa A , Merli G , Schellong S , Spyropoulos AC , Tapson V , MAGELLAN Investigators : Rivaroxaban for thromboprophylaxis in acutely ill medical patients .", "label": "", "metadata": {}, "score": "63.952698"}
{"text": "BACKGROUND : Ticagrelor is an oral , reversible , direct - acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel .", "label": "", "metadata": {}, "score": "64.06726"}
{"text": "Prescribing decisions in venous thromboembolism management may seem complex due to the large range of clinical indications and patient types , and the range of anticoagulants available .", "label": "", "metadata": {}, "score": "64.16585"}
{"text": "Guillaume Pare Population Health Research Institute , Hamilton Health Sciences , Hamilton , ON , Canada N Engl J Med 363:1704 - 14 .Double - dose versus standard - dose clopidogrel and high - dose versus low - dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT - OASIS 7 ) : a randomised factorial trial .", "label": "", "metadata": {}, "score": "64.19716"}
{"text": "The RECORD 2 [ 20 ] trial compared extended duration rivaroxaban ( 31 - 39 days ) to short - term enoxaparin ( 10 - 14 days ) in 2509 patients undergoing total hip arthroplasty .", "label": "", "metadata": {}, "score": "64.24991"}
{"text": "[ 22 ] .The first injection of fondaparinux was given 6 to 8 hours after surgical closure , and the second injection of fondaparinux was given 16 to 28 hours after the first injection ; an epidural , if used , was removed 2 hours prior to the first injection .", "label": "", "metadata": {}, "score": "64.29673"}
{"text": "Clinical evidence from randomized controlled trials for the efficacy and safety of parenteral anticoagulants in the prophylaxis of VTE .bid , twice daily ; tid , three times daily ; UFH , unfractionated heparin ; VTE , venous thromboembolism .", "label": "", "metadata": {}, "score": "64.29863"}
{"text": "10.1056/NEJM198610093151503 View Article PubMed .Levine MN , Hirsh J , Gent M , Turpie AG , Leclerc J , Powers PJ , Jay RM , Neemeh J : Prevention of deep vein thrombosis after elective hip surgery .", "label": "", "metadata": {}, "score": "64.30761"}
{"text": "Based on the indirect comparison of TRITON and PLATO trial data , ticagrelor is clearly superior to prasugrel in a population ... .To determine whether changes in practice , over time , are associated with altered rates of major bleeding in acute coronary syndromes ( ACS ) .", "label": "", "metadata": {}, "score": "64.312454"}
{"text": "Theodore E Warkentin Chest 131:1620 - 2 .A replacement for warfarin : the search continues .John W Eikelboom Circulation 116:131 - 3 .Enoxaparin versus unfractionated heparin in ST - elevation myocardial infarction .", "label": "", "metadata": {}, "score": "64.40621"}
{"text": "We found two published studies that looked at ximelagatran .18 THRIVE I also reported event data .The phase III , THRIVE II and THRIVE V studies were reported together as one trial ( referred to as THRIVE II / V in this study ) .", "label": "", "metadata": {}, "score": "64.43511"}
{"text": "Firstly , the rivaroxaban studies accounted for more than 53 % of the participants in the whole meta - analysis so this finding might simply reflect the larger sample size .", "label": "", "metadata": {}, "score": "64.48621"}
{"text": "Circulation 2008 , 117 : 296 - 329 .10.1161/CIRCULATIONAHA.107.188209 View Article PubMed .Kakkar W , Cohen AT , Edmonson RA , Phillips MJ , Cooper DJ , Das SK , Maher KT , Sanderson RM , Ward VP , Kakkar S : Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery .", "label": "", "metadata": {}, "score": "64.50839"}
{"text": "RR : . relative risk .tid : . three times daily .UFH : . unfractionated heparin .VTE : . venous thromboembolism .Declarations .", "label": "", "metadata": {}, "score": "64.614075"}
{"text": "Data synthesis and analysis .Event data were pooled for recurrent acute venous thromboembolism , major bleeding , and all cause mortality .In the primary analysis we stratified the results by drug name .", "label": "", "metadata": {}, "score": "64.61611"}
{"text": "Conclusions .In conclusion , the novel oral anticoagulants had similar efficacy and mortality profiles compared with conventional anticoagulation with vitamin K antagonists .Rivaroxaban was associated with lower risk of major bleeding .", "label": "", "metadata": {}, "score": "64.63186"}
{"text": "Fourthly , durations of follow - up and treatment varied between randomised controlled trials , which could limit the interpretation of the meta - analysis for a specific length of treatment .", "label": "", "metadata": {}, "score": "64.81835"}
{"text": "Dabigatran has been associated with increased risk of myocardial infarction , though this was not specifically noted in RECOVER I. 20 Dabigatran was not associated with increased liver enzyme activity .", "label": "", "metadata": {}, "score": "64.82602"}
{"text": "Platelet ADP - receptor antagonists for cardiovascular disease : past , present and future .Nina C Raju Thrombosis Service , Hamilton General Hospital , 237 Barton Street East , Hamilton , ON L8L2X2 , Canada Nat Clin Pract Cardiovasc Med 5:766 - 80 .", "label": "", "metadata": {}, "score": "65.030846"}
{"text": "72 , no .4 , pp .581 - 592 , 2011 .View at Google Scholar .J. Trujillo - Santos , J. A. Nieto , A. Ru\u00edz - Gamietea et al . , \" Bleeding complications associated with anticoagulant therapy in patients with cancer , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "65.08261"}
{"text": "Reversal of Fondaparinux .As described before , the incidence of bleeding associated with fondaparinux ranges from 1.1 % to 7.2 % [ 27 , 28 ] .", "label": "", "metadata": {}, "score": "65.16539"}
{"text": "There were low rates of symptomatic VTE in both groups . \"Pharmacological VTE prophylaxis is recommended as the main mode of VTE prophylaxis for most hospitalized patients by the latest American College of Chest Physicians ' guidelines and there is no doubt that it will remain the most important method to prevent VTE .", "label": "", "metadata": {}, "score": "65.17958"}
{"text": "Major bleeding episodes in patients assigned to dabigatran ( 1.6 % ) were also at the same rate ( 1.9 % ) as for patients assigned to warfarin ( hazard ratio with dabigatran , 0.82 ; 95 % CI , 0.45 to 1.48 ) .", "label": "", "metadata": {}, "score": "65.21162"}
{"text": "LMWH is associated with a reduced rate of adverse effects and have replaced the use of heparin for several indications .Since heparin and LMWH are available only for parenteral use , continuous attempts have been made to develop the oral alternatives of these medications .", "label": "", "metadata": {}, "score": "65.24568"}
{"text": "Circ J 2011 , 75(8):1852 - 1859 .10.1253/circj . CJ-10 - 1183 View Article PubMed .Goldhaber SZ , Leizorovicz A , Kakkar AK , Haas SK , Merli G , Knabb RM , Weitz JI : Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients .", "label": "", "metadata": {}, "score": "65.42215"}
{"text": "N Engl J Med .Budaj A , Eikelboom JW , Mehta SR , Afzal R , Chrolavicius S , Bassand JP , Fox KA , Wallentin L , Peters RJ , Granger CB , Joyner CD , Yusuf S. Improving clinical outcomes by reducing bleeding in patients with non - ST - elevation acute coronary syndromes .", "label": "", "metadata": {}, "score": "65.479126"}
{"text": "Chong BH , Brighton TA , Baker RI , Thurlow P , Lee CH , ASTH DVT Study Group : Once - daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep - vein thrombosis .", "label": "", "metadata": {}, "score": "65.50914"}
{"text": "The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long - Term Anticoagulant Therapy ( RE - LY ) trial ... .", "label": "", "metadata": {}, "score": "65.660675"}
{"text": "PubMed .N Engl J Med 2003 , 349 : 146 - 153 .10.1056/NEJMoa025313 View Article PubMed .Maddineni J , Walenga JM , Jeske WP , Hoppensteadt DA , Fareed J , Wahi R , Bick RL : Product individuality of commercially available low - molecular - weight heparins and their generic versions : therapeutic implications .", "label": "", "metadata": {}, "score": "65.75568"}
{"text": "NAPc2 : An 85-amino acid polypeptide that was originally isolated from the canine hookworm , Ancylostoma caninum .NAPc2 binds to a noncatalytic site on factor X or factor Xa .", "label": "", "metadata": {}, "score": "65.887436"}
{"text": "Magdalena Sobieraj - Teague McMaster University , Hamilton , Ontario , Canada Semin Thromb Hemost 35:515 - 24 .A new vitamin K antagonist ( ATI-5923 ) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial .", "label": "", "metadata": {}, "score": "65.944824"}
{"text": "Medically ill patients .Orthopedic surgery .Apixaban for the Prevention of Thrombosis - related Events ( ADVANCE ) 1 [ 9 ] assigned 1599patients to receive 2.5 mg twice daily apixaban 12 to 24 hours following knee replacement surgery while 1596 patients received enoxaparin 30 mg subcutaneously twice daily .", "label": "", "metadata": {}, "score": "66.12167"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Epidemiological evidence that the risk of coronary heart disease is inversely associated with the level of high - density lipoprotein cholesterol ( HDL - C ) has motivated several phase III programmes with cholesteryl ester transfer protein ( CETP ) inhibitors .", "label": "", "metadata": {}, "score": "66.12614"}
{"text": "Tinzaparin is licensed for the inpatient treatment of DVT with or without PE [ 51 ] ( Table 1 ) .A study comparing tinzaparin 175 IU once daily with dalteparin 200 IU once daily for outpatient treatment of DVT and/or PE reported no significant difference in the incidence of recurrent VTE or major bleeding between the two LMWHs [ 57 ] .", "label": "", "metadata": {}, "score": "66.12903"}
{"text": "The ExTRACT - TIMI 25 ( Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis In Myocardial ... .OBJECTIVES :We assessed the incidence , predictors , and outcomes of gastrointestinal bleeding ( GIB ) in patients with acute coronary syndromes ( ACS ) .", "label": "", "metadata": {}, "score": "66.16202"}
{"text": "10.1002/bjs.5154 View Article PubMed .Prophylaxis in Medical Patients with Enoxaparin Study Group .N Engl J Med 1999 , 341 : 793 - 800 .", "label": "", "metadata": {}, "score": "66.31421"}
{"text": "In conclusion , our data indicate that major bleeding in hospitalized patients is a robust marker for increased risk of death , even when the bleeding itself is not life threatening .", "label": "", "metadata": {}, "score": "66.430695"}
{"text": "The primary efficacy outcome ( total VTE or death ) occurred in 6 % , 8.6 % and 6.7 % of patients in the dabigatran 220 mg , 150 mg and enoxaparin groups , respectively .", "label": "", "metadata": {}, "score": "66.432526"}
{"text": "10.1016/S0140 - 6736(02)08648 - 8 View Article PubMed .Leclerc JR , Geerts WH , Desjardins L , Laflamme GH , L'Esp\u00e9rance B , Demers C , Kassis J , Cruickshank M , Whitman L , Delorme F : Prevention of venous thromboembolism after knee arthroplasty .", "label": "", "metadata": {}, "score": "66.50524"}
{"text": "Secondary analysis : stratification by pharmacological class .In the major bleeding analysis , events occurred less often with both the direct thrombin inhibitors ( relative risk 0.68 , 95 % confidence interval 0.48 to 0.98 ) and the factor Xa inhibitors ( 0.59 , 0.40 to 0.85 ) .", "label": "", "metadata": {}, "score": "66.54851"}
{"text": "The RENOVATE II trial [ 47 ] compared 28 to 35 days of treatment with dabigatran 220 mg once daily with subcutaneous enoxaparin 40 mg once daily for prevention of VTE in 2055 patients undergoing total hip arthroplasty .", "label": "", "metadata": {}, "score": "66.66066"}
{"text": "86 - 91 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent vascular events ( VEs ) .", "label": "", "metadata": {}, "score": "66.87396"}
{"text": "Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves .John W Eikelboom Department of Medicine , McMaster University , Hamilton , ON , Canada Am J Hematol 87:S100 - 7 .", "label": "", "metadata": {}, "score": "66.881454"}
{"text": "Heit JA .The epidemiology of venous thromboembolism in the com- munity .Arterioscler Thromb Vasc Biol .Zhan C , Miller MR .Excess length of stay , charges , and mortality attrib- utable to medical injuries during hospitalization .", "label": "", "metadata": {}, "score": "66.88774"}
{"text": "Aspirin resistance : a new independent predictor of vascular events ?John W Eikelboom Department of Haematology , Royal Perth Hospital , Wellington Street , Perth , WA 6001 , Australia J Am Coll Cardiol 41:966 - 8 .", "label": "", "metadata": {}, "score": "66.96081"}
{"text": "The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries .Patients were eligible to be enrolled into the registry if they were at least 18 years old , had a symptomatic , objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis , pulmonary embolism or both .", "label": "", "metadata": {}, "score": "67.02585"}
{"text": "The ADVANCE 2 [ 10 ] recruited 3057 knee replacement patients to receive the same apixaban dose or enoxaparin 40 mg daily .The Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism 3 ( ADVANCE-3 ) trial [ 11 ] compared 5407 patients undergoing hip arthroplasty to receive either 2.5 mg twice daily apixaban or 40 mg once daily enoxaparin for 5 weeks post - surgery .", "label": "", "metadata": {}, "score": "67.17161"}
{"text": "Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation .John W Eikelboom Population Health Research Institute , McMaster University , 237 Barton St East , Hamilton , Ontario , Canada J Am Coll Cardiol 62:900 - 8 .", "label": "", "metadata": {}, "score": "67.22142"}
{"text": "11 , 2004 .View at Google Scholar \u00b7 View at Scopus . F. F. van Doormaal , G. E. Raskob , B. L. Davidson et al . , \" Treatment of venous thromboembolism in patients with cancer : subgroup analysis of the Matisse clinical trials , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "67.27681"}
{"text": "2008;133(suppl):381S-453S. Rao SV , Eikelboom JA , Granger CB , Harrington RA , Califf RM , Bassand JP .Bleeding and blood transfusion issues in patients with non - ST- segment elevation acute coronary syndromes .", "label": "", "metadata": {}, "score": "67.344666"}
{"text": "BACKGROUND : Randomized trials have established efficacy of clopidogrel in various types of acute coronary syndromes ( ACS ) .The objective of this study was to examine the temporal trends and patterns of early clopidogrel use ( within the first 24 hours of hospitalization ) across the spectrum of patients with ACS in Canada .", "label": "", "metadata": {}, "score": "67.53717"}
{"text": "Table 1 : Summary of guidelines for prevention and treatment of venous thromboembolism in cancer [ 5 - 8 ] .Currently , prophylaxis for catheter - related thrombosis is not recommended owing to conflicting evidence and a lack of major clinical trials [ 10 ] .", "label": "", "metadata": {}, "score": "67.557465"}
{"text": "Until further evidence is available in cancer patients with extremes of body weight and BMI , data presented by the pool analysis should be interpreted with caution .", "label": "", "metadata": {}, "score": "67.648796"}
{"text": "HIT antibodies were absent in all patients ; five patients were classified as unlikely to have HIT , whereas two patients were classified as possibly having HIT .", "label": "", "metadata": {}, "score": "67.67409"}
{"text": "Geerts WH , Bergqvist D , Pineo GF , Heit JA , Samama CM , Lassen MR , Colwell CW , American College of Chest Physicians : Prevention of venous thromboembolism : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines ( 8th Edition ) .", "label": "", "metadata": {}, "score": "67.74827"}
{"text": "Currently , both the ACCP and IUA guidelines recommend prophylaxis extended beyond hospitalization to up to 35 days in specific patient groups , such as patients undergoing major elective orthopedic surgical procedures or major surgery for cancer [ 6 , 8 ] .", "label": "", "metadata": {}, "score": "67.82822"}
{"text": "Ann Intern Med 1996 , 124 : 619 - 626 .View Article PubMed .Fitzgerald RH Jr , Spiro TE , Trowbridge AA , Gardiner GA Jr , Whitsett TL , O'Connell MB , Ohar JA , Young TR , Enoxaparin Clinical Trial Group : Prevention of venous thromboembolic disease following primary total knee arthroplasty .", "label": "", "metadata": {}, "score": "67.86901"}
{"text": "28],[34 ] As such , we have to interpret the benefit to risk ratio of many pharmacological VTE prophylactic agents when applied to hospitalized elderly patients with caution .", "label": "", "metadata": {}, "score": "67.969025"}
{"text": "The available evidence from the phase 3 RCTs was summarized on the basis of individual drug and the medical conditions categorized into \" atrial fibrillation \" , \" acute coronary syndrome \" , \" orthopedic surgery \" , \" venous thromboembolism \" and \" medically ill patients \" .", "label": "", "metadata": {}, "score": "68.03157"}
{"text": "Hospitals have the potential to reduce the clinical and economic burden of VTE by implementing hospital - wide protocols for the prevention and treatment of VTE .", "label": "", "metadata": {}, "score": "68.16199"}
{"text": "Creatinine clearance data are missing for 446 patients .Eikelboom et alBleeding in VTE Prevention Trials 2007 at McMaster University Library on November 2 , 2009 circ.ahajournals.orgDownloaded from .", "label": "", "metadata": {}, "score": "68.21111"}
{"text": "( up to 60 days ) and has no antidote ( Table 2 ) [ 17 , 18 ] .The van Gogh trial showed noninferiority of idraparinux versus standard of care ( UFH with VKA ) for VTE treatment ( 2.9 % versus 3.0%;OR : 0.98 , 95 % CI : 0.63 % to 1.50 % ) .", "label": "", "metadata": {}, "score": "68.27458"}
{"text": "In the historical control group , 8 of 10 patients achieved platelet recovery with no new thrombotic events or major bleeding , but 4 had limb gangrene that might have been due to inappropriate dosing of warfarin in relation to the diagnosis of HIT [ 53 ] .", "label": "", "metadata": {}, "score": "68.35148"}
{"text": "26 Thirdly , clinical trials are underway for apixaban ( clinicaltrials.gov NCT00643201 ) and edoxaban ( clinicaltrials.gov NCT009861154 ) , and further meta - analysis will be required on this subject in due course .", "label": "", "metadata": {}, "score": "68.42293"}
{"text": "Apixaban .A single published phase II study ( Botticelli study ) looked at apixaban in patients with acute deep vein thrombosis .15 This formed the basis for an ongoing clinical trial of apixaban for the treatment of acute venous thromboembolism ( clinicaltrials.gov NCT00643201 ) .", "label": "", "metadata": {}, "score": "68.44943"}
{"text": "Our study has several potential limitations .Firstly , we pooled studies with both deep vein thrombosis and pulmonary embolism under the umbrella diagnosis of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "68.49357"}
{"text": "In the third model , we used logistic regression to develop a propensity score for major bleeding that included all the prespecified baseline characteristics and cointerventions as the inde- pendent variables ( all variables retained in the model ) and major bleeding as the dependent variable .", "label": "", "metadata": {}, "score": "68.539856"}
{"text": "The two PPI that reduced the efflux ratio of dabigatran to the greatest and least extent , respectively , were used during the second part of the study , comprising a single - centre , randomised , open - label study with an incomplete Latin square design .", "label": "", "metadata": {}, "score": "68.60361"}
{"text": "The cost of rVIIa use in treatment of minor - to - moderate bleeding events in patients with hemophilia has been reported to be $ 30,818.00", "label": "", "metadata": {}, "score": "68.644684"}
{"text": "Heparin - induced thrombocytopenia ( HIT ) is an immune - mediated disorder caused by immunoglobulin G ( IgG ) antibodies that bind to platelet factor 4 ( PF4 ) , resulting in the generation and release of procoagulant microparticles such as thrombin [ 44 ] .", "label": "", "metadata": {}, "score": "68.79025"}
{"text": "Notes .Cite this as : BMJ 2012;345:e7498 .Footnotes .BDF is supported in part by the William Pencer Family Foundation .AS is supported by the Azrieli Foundation and a Susan Raymer cardiology fellowship grant .", "label": "", "metadata": {}, "score": "68.90041"}
{"text": "Dabigatran .Patients in the RECOVER I study had a higher rate of discontinuation because of dyspepsia in the dabigatran arm ( 2.9 % v 0.6 % for vitamin K antagonists ) .", "label": "", "metadata": {}, "score": "69.280914"}
{"text": "Bleeding is a strong predictor of death in patients hospitalized for arterial thrombosis who are treated with antithrombotic therapy , but the prognostic importance of bleeding in patients receiving antithrombotic prophylaxis for venous thromboembolism is uncertain .", "label": "", "metadata": {}, "score": "69.36736"}
{"text": "Geerts WH , Bergqvist D , Pineo GF , Heit JA , Samama CM , Lassen MR , Colwell CW .Prevention of venous thromboembolism : American College of Chest Physicians evidence - based clinical practice guidelines ( 8th edition ) .", "label": "", "metadata": {}, "score": "69.51716"}
{"text": "The period of increased thrombotic risk may be sustained by the presence of ongoing risk factors such as malignancy or immobility [ 1 ] .In addition , the risk of recurrent VTE is high , with nearly one - third of patients experiencing a recurrent event within 8 years [ 4 ] .", "label": "", "metadata": {}, "score": "69.54356"}
{"text": "Combined antiplatelet and anticoagulant therapy : clinical benefits and risks .J W Eikelboom Thrombosis Service , Hamilton General Hospital , Hamilton , ON , Canada J Thromb Haemost 5:255 - 63 .", "label": "", "metadata": {}, "score": "69.64989"}
{"text": "6 , pp .1191 - 1194 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed . I. Gouin - Thibault , E. Pautas , I. Mah\u00e9 et al . , \" Is modification of diet in renal disease formula similar to Cockcroft - Gault formula to assess renal function in elderly hospitalized patients treated with low - molecular - weight heparin ? \" Journals of Gerontology - Series A , vol .", "label": "", "metadata": {}, "score": "69.65398"}
{"text": "10.1002/ajh.20983 View Article PubMed .Spencer FA , Lessard D , Emery C , Reed G , Goldberg RJ : Venous thromboembolism in the outpatient setting .", "label": "", "metadata": {}, "score": "69.73526"}
{"text": "When there were no events in one treatment group , we used a 0.5 continuity correction .We also calculated the I 2 statistic to estimate the proportion of variation attributable to heterogeneity between studies .", "label": "", "metadata": {}, "score": "69.825966"}
{"text": "The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement .", "label": "", "metadata": {}, "score": "69.92134"}
{"text": "It should be used cautiously in patients with severely impaired renal function .It has no effect on the QTc interval [ 17 ] .Medically ill patients .", "label": "", "metadata": {}, "score": "69.99718"}
{"text": "Elderly patients have higher risk of VTE because of the high prevalence of predisposing co - morbidities and acute illnesses .Clinical diagnosis of VTE in the elderly patient is particularly difficult and , as such , adequate VTE prophylaxis is of pivotal importance in reducing the mortality and morbidities of VTE .", "label": "", "metadata": {}, "score": "70.03723"}
{"text": "10.1016/j.clpt.2005.06.011 View Article PubMed .Kubitza D , Mueck W , Becka M : Randomized , double - blind , crossover study to investigate the effect of rivaroxaban on QT - interval prolongation .", "label": "", "metadata": {}, "score": "70.04401"}
{"text": "Wide therapeutic window .No dose adjustment required .Minimal or no interaction with food or other drugs .Inhibition of both free and clot - bound activated coagulation factors .", "label": "", "metadata": {}, "score": "70.16307"}
{"text": "10.1001/archinte.163.11.1337 View Article PubMed .Singelyn FJ , Verheyen CC , Piovella F , Van Aken HK , Rosencher N , EXPERT Study Investigators .", "label": "", "metadata": {}, "score": "70.36368"}
{"text": "Graeme J Hankey BMJ 328:477 - 9 .Failure of aspirin to prevent atherothrombosis : potential mechanisms and implications for clinical practice .John W Eikelboom Department of Haematology , Royal Perth Hospital , Box X2213 GPO , Perth , WA 6001 , Australia Am J Cardiovasc Drugs 4:57 - 67 .", "label": "", "metadata": {}, "score": "70.37367"}
{"text": "Completed randomized controlled trials investigating the effect of triple versus dual antiplatelet therapy ... .During 2009 , multiple major cardiology trials have been presented or published .", "label": "", "metadata": {}, "score": "70.38055"}
{"text": "PubMed .Lausen I , Jensen R , Jorgensen LN , Rasmussen MS , Lyng KM , Andersen M , Raaschou HO , Wille - J\u00f8rgensen P : Incidence and prevention of deep venous thrombosis occurring late after general surgery : randomised controlled study of prolonged thromboprophylaxis .", "label": "", "metadata": {}, "score": "70.48287"}
{"text": "Dabigatran versus warfarin in patients with atrial fibrillation .Stuart J Connolly Population Health Research Institute , McMaster University and Hamilton Health Sciences , Hamilton , ON , Canada N Engl J Med 361:1139 - 51 .", "label": "", "metadata": {}, "score": "70.62208"}
{"text": "Adding aspirin to clopidogrel after TIA and ischemic stroke : benefits do not match risks .Graeme J Hankey Stroke Unit , Department of Neurology , Royal Perth Hospital , Perth , Australia Neurology 64:1117 - 21 .", "label": "", "metadata": {}, "score": "70.62323"}
{"text": "Transient thrombocytopenia due to chemotherapy doubles the bleeding risk from 10 % at a platelet count of 20,000/mm 3 to 20 % when the platelet count drops below 10,000/mm 3 in solid tumor patients [ 59 ] .", "label": "", "metadata": {}, "score": "70.65262"}
{"text": "The patient received the dose of rVIIa prior to craniotomy for evacuation of a cranial hematoma ; however , the patient did not survive the trauma due to increasing intracranial pressure following craniotomy [ 67 ] .", "label": "", "metadata": {}, "score": "70.69419"}
{"text": "Mechanical VTE prophylaxis , including calf and thigh compression devices and/or an inferior vena cava filter , are often underutilized in hospitalized elderly patients who are at high - risk of bleeding and VTE .", "label": "", "metadata": {}, "score": "70.72125"}
{"text": "Trial registration Registered in DRKS register , ID number : DRKS00004795 .[ Show abstract ] [ Hide abstract ] ABSTRACT : The aim of this study was quantify the drug - drug interactions between dabigatran etexilate ( DE ) and proton pump inhibitors ( PPI ) and in particular the role of P - gp activity modulation .", "label": "", "metadata": {}, "score": "70.82036"}
{"text": "Weitz JI , Eikelboom JW , Samama MM , American College of Chest Physicians .New antithrombotic drugs : antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines .", "label": "", "metadata": {}, "score": "70.95817"}
{"text": "Recurrent VTE in six - month subgroup analysis of cancer patients enrolled in of the van Gogh trial was 2.5 % in the idraparinux group compared to 6.4 % in the standard of care group ( hazard ration 0.39 , 95%CI : 0.14 - 1.11 ) .", "label": "", "metadata": {}, "score": "71.0704"}
{"text": "The absorption of this drug is not affected by food intake and it is eliminated primarily through fecal ( 75 % ) but also through renal ( 25 % ) pathway [ 4 ] .", "label": "", "metadata": {}, "score": "71.11174"}
{"text": "Kearon C , Kahn SR , Agnelli G , Goldhaber S , Raskob GE , Comerota AJ , American College of Chest Physicians : Antithrombotic therapy for venous thromboembolic disease : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines ( 8th Edition ) .", "label": "", "metadata": {}, "score": "71.13556"}
{"text": "133 , no .6 , pp .381S-453S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .C. Kearon , S. R. Kahn , G. Agnelli , S. Goldhaber , G. E. Raskob , and A. J. Comerota , \" Antithrombotic therapy for venous thromboembolic disease : American College of Chest Physicians evidence - based clinical practice guidelines ( 8th edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "71.22576"}
{"text": "John Eikelboom Thrombosis Service , Hamilton General Hospital Clin Adv Hematol Oncol 4:268 - 70 .Genetic determinants of dabigatran plasma levels and their relation to bleeding .", "label": "", "metadata": {}, "score": "71.34799"}
{"text": "The reasons for the increased mortality in patients enrolled in VTE prevention trials who develop major bleeding remain uncertain .Massive bleeding can lead directly to death , but in our study only 6 % of all deaths after bleeding were directly attributed to the acute bleeding event .", "label": "", "metadata": {}, "score": "71.37507"}
{"text": "The Randomized Evaluation of Long - term Anticoagulant Therapy ( RE - LY ) trial [ 49 ] enrolled 18,113 patients with atrial fibrillation who were at risk for stroke .", "label": "", "metadata": {}, "score": "71.65718"}
{"text": "Table 3 .Evidence from clinical trials of the efficacy and safety of parenteral anticoagulants in the treatment of VTE .bid , twice daily ; DVT , deep - vein thrombosis ; IV , intravenous ; PE , pulmonary embolism ; UFH , unfractionated heparin ; VTE , venous thromboembolism .", "label": "", "metadata": {}, "score": "71.695984"}
{"text": "PURPOSE OF REVIEW : Bleeding has recently been identified as a major adverse outcome in patients with acute coronary syndromes .In this review , the importance of the association of bleeding with mortality and strategies to reduce bleeding with percutaneous coronary intervention are discussed .", "label": "", "metadata": {}, "score": "71.745346"}
{"text": "Disclosures Dr Eikelboom has received honoraria and/or research funding from GlaxoSmithKline and Sanofi - Aventis .Drs Quinlan and O'Donnell do not have any disclosures .", "label": "", "metadata": {}, "score": "71.9149"}
{"text": "Female patients with atrial fibrillation are at increased stroke risk compared with male patients , and the underlying reasons for higher risk are uncertain ... .", "label": "", "metadata": {}, "score": "72.01239"}
{"text": "Wai Khoon Ho Department of Haematology , Royal Perth Hospital , Perth , Australia Expert Opin Pharmacother 5:493 - 503 .The combination of clopidogrel and aspirin should be considered in patients with non - ST - segment elevation acute coronary syndrome or undergoing percutaneous coronary intervention ... .", "label": "", "metadata": {}, "score": "72.05876"}
{"text": "The non - inferiority design has certain advantages , such as potentially reducing the sample size , and the results can often be sufficient to obtain regulatory approval , but there are important nuances to their interpretation .", "label": "", "metadata": {}, "score": "72.105125"}
{"text": "PubMed Central View Article PubMed .Raghavan N , Frost CE , Yu Z , He K , Zhang H , Humphreys WG , Pinto D , Chen S , Bonacorsi S , Wong PC , Zhang D : Apixaban metabolism and pharmacokinetics after oral administration to humans .", "label": "", "metadata": {}, "score": "72.14962"}
{"text": "This article is protected by copyright .All rights reserved .Full - text \u00b7 Article \u00b7 Sep 2015 \u00b7 Fundamental and Clinical Pharmacology .[ Show abstract ] [ Hide abstract ] ABSTRACT : The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain .", "label": "", "metadata": {}, "score": "72.150955"}
{"text": "Guidelines for anticoagulant use in acute coronary syndromes .John Eikelboom Thrombosis Service , Hamilton General Hospital , Hamilton , Ont , Canada , L8L 2X2 Lancet 371:1559 - 61 .", "label": "", "metadata": {}, "score": "72.17201"}
{"text": "A randomised , double - blind , non - inferiority trial .Thromb Haemost 2011 , 105(4):721 - 729 .10.1160/TH10 - 10 - 0679", "label": "", "metadata": {}, "score": "72.21889"}
{"text": "Fifthly , in common with many clinical trials , study participants might have been younger , healthier , and more closely monitored than the general population with acute venous thromboembolism .", "label": "", "metadata": {}, "score": "72.32193"}
{"text": "In this case series , time to platelet recovery was between 2 and 9 days , with no new thrombotic activity or major bleeding [ 50 ] .", "label": "", "metadata": {}, "score": "72.33356"}
{"text": "346 - 348 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. E. Warkentin , A. Greinacher , A. Koster , and A. M. Lincoff , \" Treatment and prevention of heparin - induced thrombocytopenia : American College of Chest Physicians evidence - based clinical practice guidelines ( 8th edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "72.39273"}
{"text": "( dabigatran OR BIBR1048 ) OR ximelagatran OR AZD0837 ; # 3 . # 2 OR # 1 ; # 4 . # 3 AND # 4 .", "label": "", "metadata": {}, "score": "72.58967"}
{"text": "The Long - Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation ( RELY - ABLE )Study .Stuart J Connolly Population Health Research Institute , McMaster University and Hamilton Health Sciences , Hamilton Circulation 128:237 - 43 .", "label": "", "metadata": {}, "score": "72.71097"}
{"text": "Data were extracted independently by two investigators .An adjusted indirect comparison was performed to compare between novel oral anticoagulants .Data sources Medline , Embase , and Cochrane Library ( from inception to April 2012 ) .", "label": "", "metadata": {}, "score": "72.72071"}
{"text": "Similarly , after lower limb orthopaedic surgery patients have a lower risk of first acute venous thromboembolism ( 0.5 - 1.0 % ) than the higher risk of recurrent acute venous thromboembolism seen in the trials analysed in our study ( 1.4 - 4.6 % ) .", "label": "", "metadata": {}, "score": "72.88482"}
{"text": "Safety endpoints were major bleeding and all cause mortality .If a study was designed as a dose finding study , we extracted data only for the dose that was used in subsequent clinical trials .", "label": "", "metadata": {}, "score": "73.034035"}
{"text": "The EINSTEIN study group introduced a novel endpoint \" net clinical benefit , \" a composite of recurrent acute venous thromboembolism and major bleeding .13 14 This parameter was not reported in other trials , and without patient level data we can not calculate the net clinical benefit simply by adding acute venous thromboembolism and major bleeding events ( H R Buller , personal communication ) .", "label": "", "metadata": {}, "score": "73.08847"}
{"text": "Publications 115 found , 100 shown here .Organ - specific bleeding patterns of anticoagulant therapy : lessons from clinical trials .Thomas Vanassche John Eikelboom , 237 Barton Street East , Hamilton , ON , L9 K 1H8 , Canada , Tel 1 905 527 4322 ext 40323 , Fax 1 905 521 1551 , E mail Thromb Haemost 112:918 - 23 .", "label": "", "metadata": {}, "score": "73.19076"}
{"text": "Arch Intern Med 2002 , 162 : 1833 - 1840 .10.1001/archinte.162.16.1833 View Article PubMed .White RH , Romano PS , Zhou H , Rodrigo J , Bargar W : Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty .", "label": "", "metadata": {}, "score": "73.29817"}
{"text": "The ENGAGE - AF - TIMI48 is a phase 3 noninferiority design megatrial that is comparing edoxaban ( 30 mg or 60 mg once daily ) or warfarin ( titrated to an INR of 2.0 to 3.0 ) in preventing thromboembolism among 20,500 patients of atrial fibrillation [ 36 ] .", "label": "", "metadata": {}, "score": "73.29882"}
{"text": "After the phase II studies , the EINSTEIN investigators chose to load rivaroxaban at 15 mg twice a day for two weeks followed 20 mg four times a day for the remainder of the study .", "label": "", "metadata": {}, "score": "73.365814"}
{"text": "In this multicenter , double - blind , randomized trial , we compared ticagrelor ( 180-mg loading dose , 90 mg twice daily thereafter ) and clopidogrel ( 300-to-600-mg loading dose , ... .", "label": "", "metadata": {}, "score": "73.384094"}
{"text": "Tinzaparine ou Heparine Standard : Evaluations dans l'Embolie Pulmonaire .N Engl J Med 1997 , 337 : 663 - 669 .10.1056/NEJM199709043371002 View Article .", "label": "", "metadata": {}, "score": "73.490166"}
{"text": "After we reviewed 20 full text articles , nine studies with over 16 000 patients were suitable for data extraction and pooled analysis .11 12 13 14 15 16 17 18 19 Four studies were phase II dose finding studies and five were phase III studies powered for non - inferiority against vitamin K antagonists .", "label": "", "metadata": {}, "score": "73.579"}
{"text": "Low molecular weight heparins and heparinoids .John W Eikelboom Department of Haematology , Royal Perth Hospital , GPO Box X2213 , Perth , WA 6001 , Australia Med J Aust 177:379 - 83 .", "label": "", "metadata": {}, "score": "73.60794"}
{"text": "In order to evaluate the risk of MI or ACS with dabigatran , a meta - analysis of seven trials of dabigatran was conducted [ 51 ] .", "label": "", "metadata": {}, "score": "73.775696"}
{"text": "Statistical analyses were performed with the use of SAS version 9.1 ( SAS Institute , Inc , Cary , NC ) .Results Trial Details The main features of the 8 phase III ( n ? 13 085 patients ) trials10 - 17are summarized in Table 1 . 314 ) or did not develop major bleeding ( n ?", "label": "", "metadata": {}, "score": "73.83785"}
{"text": "Table 1 .Characteristics of studies of novel oral anticoagulants for treatment of acute venous thromboembolism , grouped by class and drug name .Patients ' characteristics .", "label": "", "metadata": {}, "score": "73.87376"}
{"text": "We used the DerSimonian and Laird random effects model , which accounts for variability both within studies and between studies , to estimate pooled risk ratios with their 95 % confidence intervals for event data .", "label": "", "metadata": {}, "score": "74.14966"}
{"text": "Fondaparinux in the treatment of acute coronary syndromes : evidence from OASIS 5 and 6 .Ganesan Karthikeyan Hamilton General Hospital , 237 Barton Street East , Hamilton , Ontario , Canada Expert Rev Cardiovasc Ther 7:241 - 9 .", "label": "", "metadata": {}, "score": "74.453354"}
{"text": "First , male sex , lower body weight , and renal dysfunction were significant baseline predictors of major bleeding in high - risk medical or surgical patients enrolled in VTE prevention trials .", "label": "", "metadata": {}, "score": "74.50041"}
{"text": "Cardiovascular Disease Educational and Research Trust ; Cyprus Cardiovascular Disease Educational and Research Trust ; European Venous Forum ; International Surgical Thrombosis Forum ; International Union of Angiology ; Union Internationale de Phl\u00e9bologie : Prevention and treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "74.62246"}
{"text": "INTRODUCTION : .INTRODUCTION A better understanding of the molecular mechanisms underlying blood coagulation , recombinant DNA technology , isolation and characterization of anticoagulant proteins , and improvements in structure - based drug design have accelerated the pace of drug discovery .", "label": "", "metadata": {}, "score": "74.64909"}
{"text": "We restricted our primary analyses to the association between major bleeding and death , thereby ensuring that exposure ( bleeding ) pre-ceded outcome ( mortality ) .", "label": "", "metadata": {}, "score": "74.67053"}
{"text": "Antiplatelet therapy and cardiac surgery : review of recent evidence and clinical implications .David Fitchett Division of Cardiology , St Michael s Hospital , University of Toronto , Toronto , Ontario , Canada Can J Cardiol 29:1042 - 7 .", "label": "", "metadata": {}, "score": "74.823074"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants ( DOACs ) .", "label": "", "metadata": {}, "score": "74.84834"}
{"text": "In the fourth regression model ( primary analysis ) , we used a Cox proportional hazards model to examine the association between major bleeding and death , with death as the Table 1 .", "label": "", "metadata": {}, "score": "74.89168"}
{"text": "Extended - duration thromboprophylaxis .It has been reported that more than two - thirds of all symptomatic VTE events occur in the outpatient setting , predominantly in patients who have recently undergone surgery or been hospitalized for medical illness [ 3 ] .", "label": "", "metadata": {}, "score": "75.026436"}
{"text": "Absorption : very low bioavailability ( 3.5 - 5 % )Has very low probability with drug - drug interactions .The administration of PPI tends to decrease the absorption .", "label": "", "metadata": {}, "score": "75.11614"}
{"text": "In three of the five studies graded as having unclear potential for bias this was due to only a single domain , with all other domains classified as low potential for bias .", "label": "", "metadata": {}, "score": "75.30884"}
{"text": "Comme pour tous les anticoagulants oraux directs ( AOD ) , il ne n\u00e9cessite pas de surveillance biologique de routine , n\u00e9anmoins il peut retentir sur tous les tests de coagulation rendant l'interpr\u00e9tation de ces derniers parfois difficile .", "label": "", "metadata": {}, "score": "75.41757"}
{"text": "The overall mortality rate was 1.3 % in the fondaparinux plus IPC group ( 1 fatal pulmonary embolism ( PE ) ) and 0.8 % in the IPC group ( 1 fatal PE , . )", "label": "", "metadata": {}, "score": "75.51027"}
{"text": "Relevant details of the pharmacokinetic properties of the drugs were added to complete the drug profile independent of the above mentioned literature search .Apixaban .", "label": "", "metadata": {}, "score": "75.70417"}
{"text": "Patients Who Developed Major Bleeding ComparedWith Those Who Did Not Develop Major Bleeding Baseline Characteristics and Interventions Among Characteristic Major Bleeding ( n ? 314 )", "label": "", "metadata": {}, "score": "75.98545"}
{"text": "J Thromb Haemost 2008 ; 6 : 1313 -8 .Schulman S , Kakkar AK , Schellong SM , Goldhaber SZ , Henry E , Mismetti P , et al .", "label": "", "metadata": {}, "score": "76.07703"}
{"text": "BACKGROUND :The Global Registry of Acute Coronary Events ( GRACE)-a prospective , multinational study of patients hospitalized with acute coronary syndromes ( ACSs)-was designed to improve the quality of care for patients with an ACS .", "label": "", "metadata": {}, "score": "76.07704"}
{"text": "The recently released PREVENT trial provides some answers ... .Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes .Paul Cherian Department of Medicine , University of Western Australia , Perth , Australia Stroke 34:2132 - 7 .", "label": "", "metadata": {}, "score": "76.11905"}
{"text": "Mortality rates in patients with HIT and thrombosis can be as high as 30 % , and 20 % of patients who survive require a limb amputation [ 46 ] .", "label": "", "metadata": {}, "score": "76.16219"}
{"text": "Professor Fareed has received research grants from Bayer Pharma , Germany , and Gentium , Italy , and has served as a symposium speaker for sanofi - aventis , France , and King Pharma , USA .", "label": "", "metadata": {}, "score": "76.23198"}
{"text": "After a VTE event , upto one - third of patients may suffer from the post - thrombotic syndrome , which causes long - term morbidity due to leg pain , swelling , and the effects of vascular insufficiency [ 4 ] .", "label": "", "metadata": {}, "score": "76.235855"}
{"text": "Serious PE associated with hemodynamic instability has to be admitted in intensive care unit due to the need for fibrinolytics .PE without any risk factor for VTE recurrences or death could be followed as outpatient .", "label": "", "metadata": {}, "score": "76.31262"}
{"text": "The EINSTEIN - DVT study enrolled 3449 patients with acute deep vein thrombosis and excluded patients with symptomatic pulmonary embolism .13 The EINSTEIN - PE study recruited 4832 patients with acute symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis .", "label": "", "metadata": {}, "score": "76.42663"}
{"text": "The strengths of our study are that we analyzed individual patient data from a data set involving ? 13 000 patients , of whom ? 300 developed major bleeding .", "label": "", "metadata": {}, "score": "76.58335"}
{"text": "Bivalirudin : A 20-amino acid synthetic polypeptide , bivalirudin is an analog of hirudin .Bivalirudin has a plasma half - life of 25 min after IV injection , and only a fraction is excreted via the kidneys .", "label": "", "metadata": {}, "score": "76.76961"}
{"text": "Dabigatran plasma concentration and thrombin time were measured in blood samples withdrawn at 11 time points after each treatment .Models were built using a non - linear mixed - effect modelling approach .", "label": "", "metadata": {}, "score": "76.791245"}
{"text": "Initial hospitalization with ambulatory follow - up occurred in 17 French centers .Full - dose anticoagulation for at least 6 months in all patients .", "label": "", "metadata": {}, "score": "77.111984"}
{"text": "Venous thromboembolism ( VTE ) is a common disease that occurs in hospitalized surgical and medical patients and in the community [ 1 ] .In 2003 , over 12 million medical and surgical patients in the Nationwide Inpatient Sample , comprising 31 % of all US hospital discharges for that year , were at risk of VTE and warranted thromboprophylaxis [ 2 ] .", "label": "", "metadata": {}, "score": "77.2078"}
{"text": "If continuous data were not normally distributed , the Wilcoxon rank sum test was used .In the first and second models , we used forward stepwise logistic regression modeling to identify the significant baseline predictors of major bleeding and mortality , respectively .", "label": "", "metadata": {}, "score": "77.24788"}
{"text": "Atherothrombosis is the underlying pathology of the acute coronary syndromes ( ACS ) , in which platelet activation plays a key role .Therefore , antiplatelet therapy is an essential component of guideline - recommended ACS management .", "label": "", "metadata": {}, "score": "77.388214"}
{"text": "Table 2 .Participants in studies of novel oral anticoagulants ( NOA ) for treatment of acute venous thromboembolism ( VTE ) .Figures are percentages of patients unless stated otherwise , absolute numbers of patients in each group are given in table 3 .", "label": "", "metadata": {}, "score": "77.397995"}
{"text": "The objective was to examine the association between blood storage duration and in - hospital mortality in a large cohort of cardiovascular patients transfused between 2002 and 2011 ... .", "label": "", "metadata": {}, "score": "77.40025"}
{"text": "Funding :This research received no specific grant from any funding agency in the public , commercial , or not - for - profit sectors .", "label": "", "metadata": {}, "score": "77.408295"}
{"text": "Circulation .Marik PE , Corwin HL .Efficacy of red blood cell transfusion in the critically ill : a systematic review of the literature .", "label": "", "metadata": {}, "score": "77.58473"}
{"text": "Observational studies , phase 1 and phase 2 trials were excluded .We also excluded personal opinions , editorials , correspondences and perspective articles .Full text versions of the included articles were downloaded and evaluated by the authors to compile a narrative review on the field ( Figure 2 ) .", "label": "", "metadata": {}, "score": "77.79579"}
{"text": "For example , in the THRIVE II / V study , clinically silent but radiologically proved pulmonary embolism was seen in 37 % of patients , which is consistent with previous literature .", "label": "", "metadata": {}, "score": "78.072266"}
{"text": "Neurology .Manoukian SV , Voeltz MD , Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention : pre- dictors , prognostic significance , and paradigms for reducing risk .", "label": "", "metadata": {}, "score": "78.19915"}
{"text": "The aim of this study was to systematically review the published research ... .Schafer Jeremy A JA Prime Therapeutics , 1305 Corporate Center Drive , Eagan , MN 55121 , USA .", "label": "", "metadata": {}, "score": "78.30372"}
{"text": "Published by the BMJ Publishing Group Limited .[ Show abstract ] [ Hide abstract ] ABSTRACT :The initial management or venous thromboembolism ( VTE ) corresponds to the first 3 months of treatment .", "label": "", "metadata": {}, "score": "78.39157"}
{"text": "DL receives support from the Bank of Montreal Center for the Study of Heart Disease in Women , and the Dimitrious Banousis Foundation .Contributors : BDF conceived the study , performed the systematic review , data extraction , and data analysis , and drafted the manuscript .", "label": "", "metadata": {}, "score": "78.944626"}
{"text": "Page 3 . 2 elective abdominal surgery,15,17and 1 acutely ill high - risk medical patients.16 Definition of Major Bleeding We used the definitions for bleeding as described in the individual trials and did not attempt to retrospectively reclassify bleeding outcomes .", "label": "", "metadata": {}, "score": "79.05343"}
{"text": "John W Eikelboom Med J Aust 180:549 - 51 .Antiplatelet agents in acute coronary syndromes .John W Eikelboom Department of Haematology , Royal Perth Hospital and Department of Medicine , University of Western Australia , Crawley , WA , Australia Semin Vasc Med 3:403 - 14 .", "label": "", "metadata": {}, "score": "79.22197"}
{"text": "Hirudin inhibits thrombin in a bivalent fashion .The plasma half - life of hirudin is 60 min after IV injection , and 120 min after subcutaneous injection .", "label": "", "metadata": {}, "score": "79.49333"}
{"text": "Jahrestagung der Gesellschaft f\u00fcr Arzneimittelanwendungsforschung und Arzneimittelepidemiologie .Frankfurt am Main , 15.-16.11.2007 .D\u00fcsseldorf : German Medical Science GMS Publishing House ; 2007 .Doc07gaa22 .", "label": "", "metadata": {}, "score": "79.60387"}
{"text": "Use of clopidogrel post - coronary artery bypass surgery in canadian patients with acute coronary syndromes .Ahmed Krimly Terrence Donnelly Heart Centre , St Michael s Hospital , University of Toronto , Toronto , Ontario , Canada Can J Cardiol 27:711 - 5 .", "label": "", "metadata": {}, "score": "79.60616"}
{"text": "Dabigatran etexilate is an orally active pro - drug which is rapidly converted to dabigatran by esterase - mediated hydrolysis in the plasma and the liver [ 37 ] .", "label": "", "metadata": {}, "score": "79.62834"}
{"text": "Il est donc n\u00e9cessaire de pr\u00e9ciser le nom du m\u00e9dicament pour lequel le dosage est demand\u00e9 . L'absenced'antidote sp\u00e9cifique \u00e0 ces nouveaux anticoagulants rend parfois la gestion des accidents h\u00e9morragiques complexe .", "label": "", "metadata": {}, "score": "79.80126"}
{"text": "Wai Khoon Ho Royal Perth Hospital , Perth , WA Med J Aust 182:476 - 81 .The risk of recurrence is highest in people with recurrent unprovoked DVT or chronic predisposing factors ( eg , cancer ) who require indefinite anticoagulant treatment ... .", "label": "", "metadata": {}, "score": "80.0509"}
{"text": "Dr Cafer Adiguzel was a fellow of the International Union of Angiology during the preparing of this manuscript .His fellowship was partially funded by the Turkish Society of Hematology .", "label": "", "metadata": {}, "score": "80.07776"}
{"text": "11 , pp .1300 - 1305 , 2007 .View at Google Scholar .C. Melloni , E. D. Peterson , A. Y. Chen et al . , \" Cockcroft - gault versus modification of diet in renal disease .", "label": "", "metadata": {}, "score": "80.090965"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : L'apixaban est un inhibiteur direct du facteur Xa de la coagulation .La posologie recommand\u00e9e est de 5 mg deux fois par jour pouvant \u00eatre r\u00e9duite \u00e0 2,5 mg deux fois par jour selon le risque de l'individu .", "label": "", "metadata": {}, "score": "80.15036"}
{"text": "PubMed .Lassen MR , Bauer KA , Eriksson BI , Turpie AG , European Pentasaccharide Elective Surgery Study ( EPHESUS ) Steering Committee : Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip - replacement surgery : a randomised double - blind comparison .", "label": "", "metadata": {}, "score": "80.36703"}
{"text": "Lancet 1993 , 341 : 259 - 265 .10.1016/0140 - 6736(93)92614-Y View Article PubMed .Hirsh J , Bauer KA , Donati MB , Gould M , Samama MM , Weitz JI , American College of Chest Physicians : Parenteral anticoagulants : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines ( 8th Edition ) .", "label": "", "metadata": {}, "score": "80.402145"}
{"text": "John W Eikelboom Department of Medicine , McMaster University , Hamilton , ON , L9 K 1H8 , Canada Chest 141:e89S-119S. The effect of long - term homocysteine - lowering on carotid intima - media thickness and flow - mediated vasodilation in stroke patients : a randomized controlled trial and meta - analysis .", "label": "", "metadata": {}, "score": "80.66928"}
{"text": "Blood 2011 ; 118 : 205 .Eriksson H , W\u00e5hlander K , Gustafsson D , Welin LT , Frison L , Schulman S , et al .", "label": "", "metadata": {}, "score": "80.78062"}
{"text": "( Table 3 ) [ 60 ] .Table 3 : Multivariate analysis for major bleeding and bleeding risk index classification [ 60 , 61 ] .", "label": "", "metadata": {}, "score": "80.951324"}
{"text": "Beyond unfractionated heparin and warfarin : current and future advances .Jack Hirsh Henderson Research Centre , Hamilton Health Sciences Corporatin , Ontario , Canada Circulation 116:552 -", "label": "", "metadata": {}, "score": "81.00604"}
{"text": "Int Angiol 2006 , 25 : 101 - 161 .Nightingale SL : From the Food and Drug Administration .JAMA 1993 , 270 : 1672 .", "label": "", "metadata": {}, "score": "81.276474"}
{"text": "Quality assurance issues relevant to testing platelet function are reviewed in this article , with a focus on their application to established and to new and emerging tests ... .", "label": "", "metadata": {}, "score": "81.28601"}
{"text": "Patients Who Died Compared With Those Who Did Not Die Baseline Characteristics and Interventions Among CharacteristicDead ( n ?239 ) Alive ( n ? 0.0001 0.06 0.06 Data are presented as n ( % ) unless indicated otherwise .", "label": "", "metadata": {}, "score": "81.635284"}
{"text": "Antithrombotic management of patients with prosthetic heart valves : current evidence and future trends .Jack C J Sun Division of Cardiac Surgery , McMaster University , Hamilton , ON , Canada Lancet 374:565 - 76 .", "label": "", "metadata": {}, "score": "81.68031"}
{"text": "Methods .Data sources and searches .We searched Medline , Embase , and the Cochrane Library .Each database was searched from its inception date to 5 April 2012 .", "label": "", "metadata": {}, "score": "82.05417"}
{"text": "Atrial fibrillation .Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ( ARISTOTLE ) trial [ 12 ] was a comparison between apixaban ( 5 mg twice daily ) and warfarin ( titrated to an INR of 2.0 to 3.0 ) .", "label": "", "metadata": {}, "score": "82.302315"}
{"text": "J Bone Joint Surg Am 1999 , 81 : 932 - 940 .10.1302/0301 - 620X.81B5.10316 View Article PubMed .The North American Fragmin Trial Investigators .", "label": "", "metadata": {}, "score": "82.333725"}
{"text": "Patients who received intravenous tPA and continuous intravenous infusions of UFH were excluded .The primary outcome was major hemorrhage ( intracranial or extracranial ) and the secondary outcome was total hemorrhage ( major and minor hemorrhage ) during hospitalization .", "label": "", "metadata": {}, "score": "82.36072"}
{"text": "Neither of these agents has been tested in humans .Slide 21 : .Arterioscler Thromb Vasc Biol .HTTPS ( Hypertext Transfer Protocol Secure ) is a protocol used by Web servers to transfer and display Web content securely .", "label": "", "metadata": {}, "score": "82.48143"}
{"text": "John W Eikelboom McMaster University , Hamilton , ON , Canada Lancet 372:6 - 8 .Monitoring unfractionated heparin with the aPTT : time for a fresh look .", "label": "", "metadata": {}, "score": "82.524536"}
{"text": "Tinmouth A , Chin - Yee I. The clinical consequences of the red cell storage lesion .Transfus Med Rev. 2001;15:91 - 107 .Koch CG , Li L , Sessler DI , Figueroa P , Hoeltge GA , Mihaljevic T , Blackstone EH .", "label": "", "metadata": {}, "score": "82.83234"}
{"text": "Clinical usefulness of plasma homocysteine in vascular disease .Graeme J Hankey Department of Neurology , Royal Perth Hospital , Wellington Street , Perth , Western Australia , 6001 Med J Aust 181:314 - 8 .", "label": "", "metadata": {}, "score": "83.0766"}
{"text": "The manuscript was drafted with reference to the preferred reporting items for systematic reviews and meta - analyses ( PRISMA ) checklist .Results .Study characteristics .", "label": "", "metadata": {}, "score": "83.30154"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Venous thromboembolism ( VTE ) is a major health problem , with over one million events every year in Europe .", "label": "", "metadata": {}, "score": "83.799934"}
{"text": "Graeme J Hankey Royal Perth Hospital , 197 Wellington Street , Perth , WA 6001 , Australia Med J Aust 178:568 -74 .Long - term management of venous thromboembolism : is there a role for low - intensity warfarin therapy ?", "label": "", "metadata": {}, "score": "84.06015"}
{"text": "John W Eikelboom Thrombosis Service , Hamilton Health Sciences , Hamilton , Ontario , Canada Circulation 114:774 - 82 .The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome ( ACS ) patients .", "label": "", "metadata": {}, "score": "84.27254"}
{"text": "Coronary artery disease , stroke , and peripheral vascular disease are known as \" atherothrombotic \" manifestations of atherosclerosis .These devastating conditions remain the major contributor of mortality and disability in a modern Western world , with estimated direct and indirect cost for 403.1 billion dollars in the United States alone .", "label": "", "metadata": {}, "score": "84.580246"}
{"text": "Eikelboom et al Bleeding in VTE Prevention Trials 2011 at McMaster University Library on November 2 , 2009 circ.ahajournals.orgDownloaded from .Data provided are for informational purposes only .", "label": "", "metadata": {}, "score": "85.4846"}
{"text": "Stuart J Connolly Population Health Research Institute , McMaster University , Hamilton , Ontario , Canada Circulation 116:449 - 55 .Pacemaker - detected atrial fibrillation in patients with pacemakers : prevalence , predictors , and current use of oral anticoagulation .", "label": "", "metadata": {}, "score": "85.622246"}
{"text": "Anesth Analg 2007 , 105 : 1540 - 1547 .ane.0000287677.95626.60 View Article PubMed .Ann Intern Med 2001 , 134 : 191 - 202 .", "label": "", "metadata": {}, "score": "85.71387"}
{"text": "The American College of Cardiology / American Heart Association and the European Society of Cardiology each recently published updated guidelines for management of patients with acute ST elevation myocardial infarction .", "label": "", "metadata": {}, "score": "85.92129"}
{"text": "Graeme J Hankey Stroke Unit , Royal Perth Hospital , 197 Wellington Street Perth , Australia 6001 Stroke 35:389 - 91 .The tissue factor pathway in ischemic stroke .", "label": "", "metadata": {}, "score": "86.164536"}
{"text": "Heart failure ( HF ) incidence approaches 10 per 1000 population after the age of 65 years , and is the most common Medicare diagnosis .", "label": "", "metadata": {}, "score": "86.24112"}
{"text": "Departments of Pathology , Loyola University Medical Center .Department of Pharmacology , Loyola University Medical Center .Department of Medicine , Division of Hematology , Marmara University Medical School .", "label": "", "metadata": {}, "score": "86.27934"}
{"text": "Filter retrieval was planned at 3 months from placement .Primary efficacy outcome was symptomatic recurrent pulmonary embolism at 3 months .Secondary outcomes were recurrent pulmonary embolism at 6 months , symptomatic deep vein thrombosis , major bleeding , death at 3 and 6 months , and filter complications .", "label": "", "metadata": {}, "score": "86.400024"}
{"text": "The authors received editorial / writing support in the preparation of this manuscript funded by sanofi - aventis U.S. , Inc. Hester van Lier , PhD , provided the editorial / writing support .", "label": "", "metadata": {}, "score": "86.47043"}
{"text": "Finally we searched clinicaltrials.gov for information on clinical trials that were terminated but unpublished .Study selection .One reviewer ( BDF ) performed the database search and initial screening of titles and abstracts .", "label": "", "metadata": {}, "score": "86.56625"}
{"text": "Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40 % of total mortality in Western countries , most of which is due to acute coronary syndromes ( ACS ) , including ST and non - ST elevation myocardial infarction .", "label": "", "metadata": {}, "score": "86.59424"}
{"text": "J Clin Pharmacol 2005 , 45(5):555 - 563 .10.1177/0091270005274550 View Article PubMed .Lancet 2007 , 370(9591):949 - 956 .10.1016/S0140 - 6736(07)61445 - 7 View Article PubMed .", "label": "", "metadata": {}, "score": "86.596016"}
{"text": "BMJ .Turpie AG , Bauer KA , Caprini JA , Comp PC , Gent M , Muntz JE .Fondaparinux combined with intermittent pneumatic compression versus intermittent pneumatic compression alone for prevention of venous 2010Circulation November 17 , 2009 at McMaster University Library on November 2 , 2009 circ.ahajournals.orgDownloaded from .", "label": "", "metadata": {}, "score": "86.66742"}
{"text": "Dabigatran is predominately ( 80 % ) excreted unchanged by the kidneys and its plasma levels are increased in patients with renal insufficiency [ 37 , 38 ] .", "label": "", "metadata": {}, "score": "86.75892"}
{"text": "Edoxaban .Edoxaban is a rapidly absorbed active drug with a half life of 9 - 11 hours [ 4 , 31 ] .An RCT has demonstrated that the effect of food on the pharmacokinetic properties of the drug is clinically insignificant [ 32 ] .", "label": "", "metadata": {}, "score": "86.876526"}
{"text": "10.1056/NEJMoa076016 View Article PubMed .Lancet 2009 , 373(9676):1673 - 1680 .10.1016/S0140 - 6736(09)60734 - 0 View Article PubMed .Eur Heart J 2011 , 32(19):2387 - 2394 .", "label": "", "metadata": {}, "score": "86.98396"}
{"text": "Cohen AT , Davidson BL , Gallus AS , Lassen MR , Prins MH , Tomkowski W , Turpie AG , Egberts JF , Lensing AW .", "label": "", "metadata": {}, "score": "87.030014"}
{"text": "Association Between Major Bleeding and Mortality ( Primary Analysis )The predictors of death are summarized in Table 4 .The mean time between bleeding and death was 6.4 days , and the median was 3.0 days .", "label": "", "metadata": {}, "score": "87.183655"}
{"text": "The PK model was based on an inverse Gaussian absorption process with one compartment .The relationship between dabigatran concentration and thrombin time was considered linear .", "label": "", "metadata": {}, "score": "87.2514"}
{"text": "However , there were no significant differences in the incidence of major bleeding events ( 0.6 % , 0.6 % , and 1.4 % , respectively ) .", "label": "", "metadata": {}, "score": "87.31734"}
{"text": "The plasma elimination half - life is 5 - 9 hours in young adults and 11 - 13 hours in older people due to the age - related decline in renal function .", "label": "", "metadata": {}, "score": "87.41209"}
{"text": "John W Eikelboom Department of Hematology , Royal Perth Hospital , Wellington Street , Perth , WA , 6001 Australia Haematologica 89:586 - 93 .Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines ... .", "label": "", "metadata": {}, "score": "87.46011"}
{"text": "Postoperative low - molecular - weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators .Marlene Robinson Department of Medicine , McMaster University , 237 Barton Street East , Hamilton , Ontario , Canada Pacing Clin Electrophysiol 32:378 - 82 .", "label": "", "metadata": {}, "score": "87.485146"}
{"text": "Table 1 . Food and Drug Administration - approved indications of parenteral anticoagulants available for the treatment and prevention of venous thromboembolism in the US .", "label": "", "metadata": {}, "score": "87.51137"}
{"text": "10.1111/j.1538 -7836.2010.04021.x View Article PubMed .Thromb Haemost 2010 , 104(3):633 - 641 .10.1160/TH10 - 01 - 0066 View Article PubMed .", "label": "", "metadata": {}, "score": "87.61474"}
{"text": "Eriksson BI , Dahl OE , Rosencher N , Kurth AA , van Dijk CN , Frostick SP , Prins MH , Hettiarachchi R , Hantel S , Schnee J , Buller HR .", "label": "", "metadata": {}, "score": "87.81235"}
{"text": "Methods GlaxoSmithKline provided access to the integrated fondaparinux database , and analyses were conducted by the company statistician .The company provided no financial support , and the authors inde- pendently developed the analysis plan , interpreted the results , wrote the article , and submitted the manuscript .", "label": "", "metadata": {}, "score": "87.92538"}
{"text": "17 As its design was similar to RECOVER I , however , we assumed that its potential bias would be either low or unclear at most .", "label": "", "metadata": {}, "score": "87.94849"}
{"text": "Dabigatran Oral capsule .Rapid onset of action .Half - life 12 - 17 hours .Plasma concentrations of dabigatran peak 0.5 - 2 hours after an oral dose .", "label": "", "metadata": {}, "score": "88.0177"}
{"text": "Table 6 .Eikelboom et alBleeding in VTE Prevention Trials 2009 at McMaster University Library on November 2 , 2009 circ.ahajournals.org Downloaded from .Page 6 .", "label": "", "metadata": {}, "score": "88.228485"}
{"text": "Follow - up data was collected by either routinely scheduled visits or by telephone calls .Overall , 381 centers participated , which enrolled 3,545 patients during an observational period of 1 year .", "label": "", "metadata": {}, "score": "88.54375"}
{"text": "Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy : a randomized feasibility trial .Jon David R Schwalm Department of Medicine , Division of Cardiology , Hamilton Health Sciences and McMaster University , 5th Floor , McMaster Clinic , 237 Barton Street East , Hamilton , ON L8L 2X2 , Canada J Thromb Thrombolysis 30:127 - 32 .", "label": "", "metadata": {}, "score": "89.02605"}
{"text": "Outcome Measure The primary outcome was death within 30 days , where day 1 corresponded to the day of randomization .Statistical Analyses Baseline characteristics among patients who developed a major bleeding event compared with those who did not develop major bleeding and among patients who died compared with those who did not die were compared with the use of a ?", "label": "", "metadata": {}, "score": "89.02646"}
{"text": "Major bleeding was defined as fatal bleeding ; bleeding that was retroperitoneal , intracranial , intraspinal , or involved any other critical organ ; bleeding that led to reoperation ; and overt bleeding with a bleeding index of ?", "label": "", "metadata": {}, "score": "89.09182"}
{"text": "Their frequency and relative importance vary according to individual patient risk profiles .We sought to develop prognostic models for the risk of myocardial infarction ( MI ) and major bleeding to assess their impact on risk of death and ... .", "label": "", "metadata": {}, "score": "89.46536"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .The authors declared that they have no competing interest .", "label": "", "metadata": {}, "score": "89.49426"}
{"text": "Table 5 shows the results of the Cox regression model of the association between major bleeding and death .After adjustment for baseline characteristics and propensity for major bleeding , the hazard for death in patients with major bleeding remained ? 7-fold higher .", "label": "", "metadata": {}, "score": "90.04655"}
{"text": "After randomization , 4 patients were lost to follow - up , all after month 18 , and 1 withdrew due to an adverse event .", "label": "", "metadata": {}, "score": "90.441284"}
{"text": "239 ) or survived ( n ? 12 846 ) at 30 days ( Table 3 ) .Predictors of Major Bleeding The predictors of major bleeding are summarized in Table 4 .", "label": "", "metadata": {}, "score": "90.59894"}
{"text": "Meta - analysis : low - molecular - weight heparin and bleeding in patients with severe renal insufficiency .Wendy Lim McMaster University and Hamilton General Hospital , Hamilton , Ontario , Canada Ann Intern Med 144:673 - 84 .", "label": "", "metadata": {}, "score": "90.72304"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b1477 - 9560 - 11 - 18 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "90.732086"}
{"text": "Two reviewers ( BDF and AS ) independently extracted data on to a computer spreadsheet , with discrepancies resolved by consensus .Extracted data included first author , year of publication , study design , characteristics of patients , length of follow - up , drug and drug loading , and maintenance protocol .", "label": "", "metadata": {}, "score": "90.79905"}
{"text": "Sonia Anand McMaster University , Hamilton , ON , Canada N Engl J Med 357:217 - 27 .Antiplatelet drugs reduce this risk , but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear ... .", "label": "", "metadata": {}, "score": "91.05502"}
{"text": "10.1001/archinte.160.2.181 View Article PubMed .N Engl J Med 2003 , 349 : 1695 - 1702 .View Article PubMed .Ann Intern Med 2004 , 140 : 867 - 873 .", "label": "", "metadata": {}, "score": "91.28079"}
{"text": "Luciana Armaganijan Department of Medicine , Cardiology Division , Arrhythmia Service , McMaster University , HHSC , David Braley CVSRI , Hamilton , Ontario , Canada Adv Ther 26:1058 - 71 .", "label": "", "metadata": {}, "score": "91.371864"}
{"text": "Conclusions - Major bleeding in hospitalized surgical and medical patients participating in venous thromboembolism prevention trials is a strong predictor of mortality .( Circulation .", "label": "", "metadata": {}, "score": "91.3996"}
{"text": "Results were similar at 6 months .No difference was observed between the 2 groups regarding the other outcomes .Filter thrombosis occurred in 3 patients .", "label": "", "metadata": {}, "score": "91.76235"}
{"text": "Susan Wan School of Medicine and Pharmacology , University of Western Australia , Perth , West Australia Circulation 110:744 - 9 .Randomized trials and meta - analyses have reached conflicting conclusions about the role of thrombolytic therapy for the treatment of acute pulmonary embolism ... .", "label": "", "metadata": {}, "score": "91.859436"}
{"text": "In this trial , 15 , 526 patients were randomized to receive either 2.5 mg or 5 mg placebo twice daily for a mean duration of 13 months .", "label": "", "metadata": {}, "score": "92.081665"}
{"text": "Log in or register : .Download this article to citation manager .Fox Benjamin D , Kahn Susan R , Langleben David , Eisenberg Mark J , Shimony Avi .", "label": "", "metadata": {}, "score": "92.14238"}
{"text": "Duration of red cell storage before transfusion and in - hospital mortality .John W Eikelboom Department of Medicine , McMaster University , Ontario , Canada Am Heart J 159:737 - 743 . e1 .", "label": "", "metadata": {}, "score": "92.269806"}
{"text": "O'Donnell MJ , Kapral MK , Fang J , Saposnik G , Eikelboom JW , Ocz- kowski W , Silva J , Gould L , D'Uva C , Silver FL .", "label": "", "metadata": {}, "score": "92.52314"}
{"text": "N Engl J Med 2010 , 363(26):2499 - 2510 .View Article PubMed .N Engl J Med 2012 , 366(14):1287 - 1297 .View Article PubMed .", "label": "", "metadata": {}, "score": "92.59099"}
{"text": "Warfarin or placebo for 18 months .The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months after randomization .", "label": "", "metadata": {}, "score": "93.13077"}
{"text": "clinicaltrials.gov Identifier : NCT00740883 .No preview \u00b7 Article \u00b7 Jul 2015 \u00b7 JAMA The Journal of the American Medical Association .[ Show abstract ] [ Hide abstract ] ABSTRACT :", "label": "", "metadata": {}, "score": "93.2022"}
{"text": "The authors would like to thank Sue Moreau from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editing this paper .", "label": "", "metadata": {}, "score": "93.32941"}
{"text": "John W Eikelboom Department of Medicine , McMaster University , Hamilton , ON , Canada Chest 135:513 - 20 .Platelet function testing : quality assurance .", "label": "", "metadata": {}, "score": "93.64955"}
{"text": "At 30 days , the risk of death was 7-fold higher among patients with a major bleeding event ( 8.6 % versus 1.7 % ; adjusted hazard ratio , 6.96 ; 95 % confidence interval , 4.60 to 10.51 ) .", "label": "", "metadata": {}, "score": "93.96341"}
{"text": "Thromboprophylaxis practice patterns in hip fracture surgery patients : experience in Perth , Western Australia .Susan Wan School of Medicine and Pharmacology , University of Western Australia , Royal Perth Hospital , Perth , Western Australia , Australia ANZ J Surg 73:826 - 9 .", "label": "", "metadata": {}, "score": "95.142746"}
{"text": "John W Eikelboom Department of Medicine , University of Western Australia , Thrombosis and Haemophilia Unit , Royal Perth Hospital , Perth , Australia Circulation 105:1650 - 5 .", "label": "", "metadata": {}, "score": "95.54866"}
{"text": "Simon J McRae The Queen Elizabeth Hospital , Institute of Medical and Veterinary Sciences , Department of Haematology Oncology , 28 Woodville Rd , Woodville 5011 , Adelaide , South Australia , Australia Expert Opin Pharmacother 8:1221 - 33 .", "label": "", "metadata": {}, "score": "95.657974"}
{"text": "Jeremy S Paikin McMaster University , Hamilton , Ontario , Canada Med J Aust 192:487 - 8 .Decisions regarding the use of triple therapy should take into account the balance between thromboembolism and bleeding risk in individual patients ... .", "label": "", "metadata": {}, "score": "96.10664"}
{"text": "Authors ' contributions .JF created the concept for the manuscript , drafted the manuscript , and approved the final manuscript .CA and IT critically revised the manuscript for important intellectual content and approved the final manuscript .", "label": "", "metadata": {}, "score": "97.119446"}
{"text": "J Arthroplasty 2009 , 24(1):1 - 9 .View Article PubMed .N Engl J Med 2009 , 361(12):1139 - 1151 .10.1056/NEJMoa0905561 View Article PubMed .", "label": "", "metadata": {}, "score": "97.19166"}
{"text": "Wai Khoon Ho Centre for Clinical Research Excellence , Department of Neurology and Department of Haematology , Royal Perth Hospital , Australia and School of Medicine and Pharmacology , University of Western Australia , Australia Blood Coagul Fibrinolysis 15:129 - 30 .", "label": "", "metadata": {}, "score": "97.23509"}
{"text": "Conclusions .Parenteral anticoagulants should be prescribed in accordance with recommended dose regimens for each clinical indication , based on the available clinical evidence for each agent to assure optimal safety and efficacy .", "label": "", "metadata": {}, "score": "97.40362"}
{"text": "Correspondence to John W. Eikelboom , Thromboembolism Unit , Sixth Floor , McMaster Wing , Hamilton General Hospital , 237 Barton St E , Hamilton , Ontario , L8L 2X2 , Canada .", "label": "", "metadata": {}, "score": "97.45201"}
{"text": "David Fitchett aSt Michael s Hospital bSouthlake Hospital , Newmarket cHamilton General Hospital , McMaster University , Hamilton dSunnybrook Hospital , University of Toronto eUniversity of Toronto , Toronto , Ontario , Canada Curr Opin Cardiol 29:1 - 9 .", "label": "", "metadata": {}, "score": "97.47584"}
{"text": "AS conceived the study , performed the systematic review , data extraction , and analysis , and reviewed the manuscript for important intellectual content .All authors had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis .", "label": "", "metadata": {}, "score": "98.017494"}
{"text": "Food does not affect its absorption from the gastrointestinal tract .It has a dual mode of elimination , since one - third of the active drug is excreted unchanged renally while two - thirds of the drug undergoes hepatic metabolism .", "label": "", "metadata": {}, "score": "98.137436"}
{"text": "Yusuf S , Mehta SR , Chrolavicius S , Afzal R , Pogue J , Granger CB , Budaj A , Peters RJ , Bassand JP , Wallentin L , Joyner C , Fox KA .", "label": "", "metadata": {}, "score": "98.36131"}
{"text": "HR devised the manuscript , FT and HR did the literature search .FT , HR and TR wrote the manuscript .IBR edited the manuscript , HM and AH did the final revision .", "label": "", "metadata": {}, "score": "98.41497"}
{"text": "Stuart J Connolly Population Health Research Institute , McMaster University , Hamilton , Ontario , Canada Circulation 118:2029 - 37 .This report examines how differences in time in therapeutic range ( TTR ) between centers and between countries affect the outcomes of OAC therapy ... .", "label": "", "metadata": {}, "score": "98.622986"}
{"text": "10.1056/NEJMoa012385 View Article PubMed .Thromb Res 1998 , 89 : 281 - 287 .10.1016/S0049 - 3848(98)00018 - 8 View Article PubMed .", "label": "", "metadata": {}, "score": "98.66327"}
{"text": "Clin Appl Thromb Hemost 2008 , 14 : 5 - 7 . 10.1177/1076029607312278 View Article PubMed .Copyright .\u00a9 Fareed et al ; licensee BioMed Central Ltd. 2011 .", "label": "", "metadata": {}, "score": "99.00134"}
{"text": "N Engl J Med 2011 , 365(10):883 - 891 .10.1056/NEJMoa1009638 View Article PubMed .Lancet 2009 , 374(9683):29 - 38 .10.1016/S0140 - 6736(09)60738 - 8 View Article PubMed .", "label": "", "metadata": {}, "score": "99.210495"}
{"text": "John Eikelboom McMaster University , Hamilton , Ontario , Canada MedGenMed 7:76 .Duration of anticoagulant therapy for venous thromboembolism .Nina C Raju Department of Medicine , McMaster University , Hamilton , Ontario , Canada Med J Aust 190:659 - 60 .", "label": "", "metadata": {}, "score": "99.21123"}
{"text": "Robby Nieuwlaat Population Health Research Institute , McMaster University , Hamilton , Ontario , Canada Thromb Res 125:e128 - 31 .We assessed to what extent generalist and specialist physicians use evidence - based methods for warfarin maintenance dosing ... .", "label": "", "metadata": {}, "score": "100.34737"}
{"text": "Spinler Sarah A SA University of the Sciences in Philadelphia , Department of Pharmacy Practice and Pharmacy Administration , 600 S. 43rd St. , Philadelphia , PA 19104 , USA .", "label": "", "metadata": {}, "score": "101.13927"}
{"text": "Shamir R Mehta Department of Medicine , Mc Master University , Hamilton Health Sciences , Hamilton , ON , Canada Can J Physiol Pharmacol 83:98 - 103 .", "label": "", "metadata": {}, "score": "101.39153"}
{"text": "10.1056/NEJMoa0906598 View Article PubMed .Copyright .\u00a9 Tahir et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Search Medline for .", "label": "", "metadata": {}, "score": "101.693954"}
{"text": "Literature search criteria .The articles were then manually examined to exclude the duplicate entries .Search was limited from January 2007 to February 2013 .", "label": "", "metadata": {}, "score": "102.089584"}
{"text": "James D Douketis Department of Medicine , McMaster University , and St Joseph s Hospital , Hamilton , Ontario , Canada L8N 4A6 Arch Intern Med 162:1465 - 71 .", "label": "", "metadata": {}, "score": "102.53877"}
{"text": "John Eikelboom Department of Medicine , University of Western Australia , Perth , Australia J Am Coll Cardiol 41:70S-78S. .70 ; 95 % confidence interval , 0.56 to 0.87 ) , with little impact on death .", "label": "", "metadata": {}, "score": "103.15578"}
{"text": "Each LMWH consists of a heterogeneous mixture of polysaccharide chains with molecular weights ranging from 2,000 to 9,000 Da ( mean 4,000 - 5,500 Da , depending on the LMWH ) .", "label": "", "metadata": {}, "score": "103.23038"}
{"text": "Labome .Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA Abstract .Background .The prevention of venous thromboembolism has been identified as a leading priority in hospital safety .", "label": "", "metadata": {}, "score": "103.27201"}
{"text": "John Eikelboom Thrombosis Service , Hamilton General Hospital , Department of Medicine , McMaster University , Hamilton , Ontario , Canada Clin Adv Hematol Oncol 5:871 - 3 .", "label": "", "metadata": {}, "score": "103.37221"}
{"text": "Stuart J Connolly Population Health Research Institute , McMaster University and Hamilton Health Sciences , Hamilton , ON , Canada N Engl J Med 364:806 - 17 .", "label": "", "metadata": {}, "score": "103.72626"}
{"text": "10.1056/NEJMoa1112277 View Article PubMed .Blood 2008 , 112(6):2242 - 2247 .10.1182/blood-2008 - 05 - 160143 View Article PubMed .Circulation 2007 , 116(2):180 - 187 .", "label": "", "metadata": {}, "score": "103.835754"}
{"text": "J W Eikelboom Department of Medicine , HGH McMaster Clinic , McMaster University , Hamilton , Ontario , Canada J Thromb Haemost 3:2649 - 55 .", "label": "", "metadata": {}, "score": "103.94971"}
{"text": "Full - text .ISSN : 1524 - 4539 Copyright \u00a9 2009 American Heart Association .All rights reserved .Print ISSN : 0009 - 7322 .", "label": "", "metadata": {}, "score": "104.18786"}
{"text": "1 , no .11 , pp .2368 - 2373 , 2003 .View at Google Scholar \u00b7 View at Scopus .91 , no . 3 , pp .", "label": "", "metadata": {}, "score": "104.691635"}
{"text": "Lancet .Spencer FA , Moscucci M , Granger CB , Gore JM , Goldberg RJ , Steg PG , Goodman SG , Budaj A , Fitzgerald G , Fox KA .", "label": "", "metadata": {}, "score": "105.096954"}
{"text": "Shoaib Amlani Department of Medicine , McMaster University , 237 Barton Street East , Hamilton , ON L8L 2X2 , Canada J Thromb Thrombolysis 30:434 - 40 .", "label": "", "metadata": {}, "score": "105.77606"}
{"text": "You are free : to Share - to copy , distribute and transmit the work , provided the original author and source are credited .Outline .", "label": "", "metadata": {}, "score": "105.828445"}
{"text": "Wendy Lim Department of Medicine , McMaster University , Hamilton , Ontario , Canada JAMA 295:1050 - 7 .Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss ... .", "label": "", "metadata": {}, "score": "105.92184"}
{"text": "25 , no .34 , pp .5490 - 5505 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .", "label": "", "metadata": {}, "score": "106.45683"}
{"text": "John W Eikelboom McMaster University , Hamilton , Ontario , Canada Circulation 118:1705 - 12 .Inherited thrombophilia and pregnancy associated venous thromboembolism .Wendy Lim Department of Medicine , McMaster University , St Joseph s Hospital , Canada BMJ 334:1318 - 21 .", "label": "", "metadata": {}, "score": "106.55027"}
{"text": "Copyright \u00a9 2014 Elsevier Masson SAS .All rights reserved .2 Division of Internal Medicine and Department of Medicine , McGill University , Center for Clinical Epidemiology and Community Studies , Lady Davis Institute , Jewish General Hospital , Montreal , QC .", "label": "", "metadata": {}, "score": "106.954346"}
{"text": "5 , pp .184 - 186 , 2005 .View at Google Scholar \u00b7 View at Scopus .3 , supplement 1 , 2005 , abstract no . P2035 .", "label": "", "metadata": {}, "score": "106.99154"}
{"text": "10.1034/j.1600 - 0404.2002.01215.x View Article PubMed .Lancet 2007 , 369 : 1347 - 1355 .10.1016/S0140 - 6736(07)60633 - 3 View Article PubMed .", "label": "", "metadata": {}, "score": "107.27563"}
{"text": "However , no study has ... .OBJECTIVE :The delay between the availability of clinical evidence and its application to the care of patients with acute coronary syndrome ( ACS ) in the Kingdom of Saudi Arabia remains undefined .", "label": "", "metadata": {}, "score": "107.41298"}
{"text": "Wai Khoon Ho Department of Haematology , Royal Perth Hospital and Centre for Clinical Research Excellence , University of Western Australia , Perth Arch Intern Med 166:729 - 36 .", "label": "", "metadata": {}, "score": "107.90697"}
{"text": "51 , no .10 , pp .991 - 996 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .", "label": "", "metadata": {}, "score": "108.20117"}
{"text": "Circulation 2004 , 110 : 874 - 879 . CIR.0000138928.83266.24View Article PubMed .BMJ 2006 , 332 : 325 - 329 .10.1136/bmj.38733.466748.7C PubMed Central View Article PubMed .", "label": "", "metadata": {}, "score": "109.60326"}
{"text": "7537 , pp .325 - 327 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "110.06234"}
{"text": "106 , no .20 , pp .2550 - 2554 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "110.1256"}
{"text": "Richard Whitlock McMaster University , Hamilton , Ontario , Canada Transfusion 53:1487 - 92 .We sought to establish if processing residual CPB volume with ultrafiltration reduces homologous blood transfusion and bleeding ... .", "label": "", "metadata": {}, "score": "110.317345"}
{"text": "Table 4 .Baseline Predictors of Major Bleeding and Death Variable ? 0.0001CI indicates confidence interval .2008Circulation November 17 , 2009 at McMaster University Library on November 2 , 2009 circ.ahajournals.orgDownloaded from .", "label": "", "metadata": {}, "score": "111.357864"}
{"text": "7272Greenville Avenue , Dallas , TX DOI : 10.1161/CIRCULATIONAHA.109.872630 published online Nov 2 , 2009 ; Circulation John W. Eikelboom , Daniel J. Quinlan and Martin O'Donnell .", "label": "", "metadata": {}, "score": "111.40109"}
{"text": "McMaster University , Ontario , Canada Stroke 39:1638 - 46 .New antithrombotic agents -- insights from clinical trials .Jeremy S Paikin Department of Medicine , McMaster University , Hamilton General Hospital , 237 Barton Street East , Hamilton , Ontario , Canada Nat Rev Cardiol 7:498 - 509 .", "label": "", "metadata": {}, "score": "112.56593"}
{"text": "100 , no . 1 , pp .26 - 31 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.65047"}
{"text": "11 , pp .876 - 878 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.83912"}
{"text": "Phone : 410 - 528 - 4050 .Permissions : Permissions & Rights Desk , Lippincott Williams & Wilkins , a division of Wolters .Page 2 .", "label": "", "metadata": {}, "score": "114.055176"}
{"text": "Jack Hirsh John W Eikelboom , Department of Medicine , McMaster University , Hamilton General Hospital , 237 Barton Street East , Hamilton , Ontario , L8L 2X2 , Canada , E mail Thromb Haemost 111:10 - 3 .", "label": "", "metadata": {}, "score": "115.33554"}
{"text": "The retrieved articles were examined to eliminate potential duplicates or overlapping data .No limits or language restriction were applied during the search .The search string was : # 1 .", "label": "", "metadata": {}, "score": "116.32647"}
{"text": "Copyright \u00a9 2011Ali Zalpour et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "116.72307"}
{"text": "The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .Publisher conditions are provided by RoMEO .", "label": "", "metadata": {}, "score": "118.937546"}
{"text": "Authors ' Affiliations .Dow Medical College , Dow University of Health Sciences .Department of Medicine , Indiana University .Department of Medicine , University of Arizona .", "label": "", "metadata": {}, "score": "122.14395"}
